N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for the treatment of CNS disorders such as multiple sclerosis

Abstract

Disclosed are N-(phenyl)-1H-indole-3-sulfonamide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of Formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g., N-pyridin-2-yl and N-pyridin-3-yl analogs thereof). The compounds possess GPR17 modulating properties useful for treating or preventing a variety of CNS and other diseases, particularly for preventing and treating myelination disorders such as multiple sclerosis.

Description

[Technical field]

[0001] Background G protein-coupled receptors (GPCRs) constitute the largest family of membrane receptors in cells. They transduce extracellular signals to intracellular effector systems and are involved in a wide variety of physiological phenomena, making them the most common targets for pharmaceutical drugs, although only a small proportion of GPCRs are currently targeted by therapeutics. [Background technology]

[0002] GPCRs respond to a wide range of ligands. With advances in human genome sequencing, defined, physiologically relevant ligands are still missing for approximately 25% of the more than 400 identified GPCRs (not including olfactory GPCRs). These receptors are known as "orphan GPCRs". "Deorphanization" and identification of their in vivo roles is expected to reveal new regulatory mechanisms and, therefore, disclose new drug targets. Whether GPR17 is such an orphan receptor is still controversial. Phylogenetically, GPR17 is closely related to the nucleotide P2Y receptors and the cysteinyl leukotriene (CysLT1, CysLT2) receptors, with amino acid sequence identity of approximately 30 to approximately 35%, respectively.

[0003] Northern blot and RT-PCR analyses of multiple tissues show predominant expression of GPR17 in the central nervous system (CNS) (Ciana et al., 2006, EMBO J 25(19):4615; Blasius et al., 1998, J Neurochem 70(4):1357) and also in the heart and kidney, organs that typically undergo ischemic injury. Two human GPR17 isoforms have been identified that differ only in the length of their N-terminus. The short GPR17 isoform encodes a 339 amino acid residue protein with seven transmembrane motifs of the typical rhodopsin type. The long isoform encodes a receptor with a 28 amino acid longer N-terminus (Blasius et al., 1998). GPR17 is highly conserved among vertebrate species (approximately 90% identity of amino acid sequence to both mouse and rat orthologues).

[0004] In the original de-orphanization report, GPR17 was: 35Based on SGTPγS binding and cAMP inhibition assays, as well as single-cell calcium imaging, it was identified as a dual receptor for uracil nucleotides and the cysteinyl leukotrienes (cysLTs) LTC4 and LTD4, respectively (Ciana et al., 2006, ibid.). Evidence for GPR17 function was provided in a variety of cell backgrounds, including 1321N1, COS7, CHO, and HEK293 cells (Ciana et al., 2006, ibid.). An independent study subsequently confirmed activation of GPR17 by uracil nucleotides, but failed to reproduce activation by CysLTs (Benned-Jensen and Rosenkilde, 2010, Br J Pharmacol, 159(5):1092). However, recent independent reports (Maekawa et al., 2009, PNAS 106(28), 11685; Qi et al., 2013, J Pharmacol Ther 347,1, 38; Hennen et al., 2013, Sci Signal 6, 298) suggested a lack of GPR17 responsiveness to both uracil nucleotides and CysLT across different cell backgrounds (1321N1, CHO, HEK293 cells) stably expressing GPR17. A novel regulatory role for GPR17 has also been proposed, where GPR17, when co-expressed with the CysLT1 receptor, renders the CysLT1 receptor insensitive to its endogenous lipid mediators LTC4 and LTD4. Additional investigations are required to more deeply explore the pharmacology and function of GPR17.

[0005] Agents that modulate GPR17 activity may have neuroprotective, anti-inflammatory, and anti-ischemic effects and may therefore be useful for the treatment of cerebral, cardiac and renal ischemia, and stroke (WO2006 / 045476) and / or improving recovery from these events (Bonfanti et al, Cell Death and Disease, 2017, 8, e2871).

[0006] GPR17 modulators are also believed to be involved in food intake, insulin and leptin responses and are therefore claimed to have a role in the treatment of obesity (WO2011 / 113032).

[0007] Furthermore, there is strong evidence that GPR17 is involved in the myelination process and that negative GPR17 modulators (antagonists or inverse agonists) may be useful drugs to treat or alleviate myelination disorders such as multiple sclerosis and spinal cord injury (Chen et al, Nature Neuroscience 2009, 12(11):1398-1406; Ceruti et al; Brain: a Journal of Neurology 2009 132(Pt8):2206-18; Hennen et al, Sci Signal, 6, 2013, 298; Simon et al J Biol Chem 291, 2016, 705; Fumagalli et al, Neuropharmacology 104, 2016, 82). More recently, two groups showed that adult GPR17- / - knockout mice remyelination was faster than wild-type littermates after LPC induced demyelination in the spinal cord (Lu et al., Nature Scientific Reports, 2018, 8:4502) or in the corpus callosum (Ou et al., J. Neurosci., 2016, 36(41):10560). In contrast, activation of GPR17 has been shown to inhibit oligodendrocyte precursor cell (OPC) maturation and prevent effective myelination (Simon et al., supra). This again confirmed the potential key role of GPR17 in the remyelination process and as a promising drug target in demyelinating diseases. Thus, the identification of potent and selective GPR17 modulators has important implications for the treatment of myelination disorders.

[0008] Several serious myelination disorders are known to be caused by either impaired myelination, loss of myelin (usually called demyelination), and / or the body's inability to properly form myelin (sometimes called hypomyelination). Myelination disorders can be idiopathic or secondary to a specific triggering event, such as traumatic brain injury or viral infection. Myelination disorders can primarily affect the central nervous system (CNS), but can also involve the peripheral nervous system. Myelination disorders include, among others, multiple sclerosis, neuromyelitis optica (also known as Devic's disease), leukodystrophy, Guillain-Barre syndrome, and many other disorders described in more detail below (see, e.g., Love, J Clin Pathol, 59, 2006, 1151; see also Fumagalli et al., supra). Neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) have also recently been strongly associated with reduced myelination (see, e.g., Ettle et al, Mol Neurobiol 53, 2016, 3046; Jellinger and Welling, Movement Disorders, 31, 2016;1767; Kang et al, Nature Neurosci 6, 2013, 571; Bartzokis, Neurochem Res (2007) 32:1655).

[0009] Multiple sclerosis (MS) is a chronic progressive disease. It is an inflammatory autoimmune disease that causes oligodendrocyte damage, demyelination, and ultimately axonal loss, thus resulting in a wide range of signs and symptoms of severe neurological disease, such as fatigue, dizziness, mobility and walking problems, difficulty speaking and swallowing, and pain. There are several forms of MS, and new symptoms either occur in isolated attacks (relapsing forms) or accumulate over time (progressive forms). While certain symptoms may disappear completely between isolated attacks, severe neurological problems often remain, especially as the disease progresses to more advanced forms. According to the Multiple Sclerosis Association of America, approximately 400,000 people in the United States and 2.5 million worldwide have been diagnosed with MS, with an estimated 10,000 new cases diagnosed in the United States each year. Multiple sclerosis is two to three times more common in women than in men.

[0010] There is no known causal cure or regimen for multiple sclerosis, or for many other myelinating disorders. Treatment is usually symptomatic, addressing the inflammatory component of the disease to improve function after attacks and prevent new attacks. Such immunomodulatory drugs are usually moderately effective, especially as the disease progresses, but they can have side effects and be poorly tolerated. Furthermore, most of the available drugs, such as beta-interferon, glatiramer acetate, or therapeutic antibodies, are only available in injectable form and / or address only the inflammatory component of the disease and not directly the demyelination. Other drugs, such as corticosteroids, have fairly non-specific anti-inflammatory and immunosuppressive effects and therefore can cause chronic side effects, such as those seen in Cushing's syndrome.

[0011] Therefore, there is a strong need for safe and effective drugs for the treatment of myelinating diseases such as MS, preferably drugs suitable for oral administration.Ideally, such drugs would reverse the demyelination process by reducing demyelination and / or promoting remyelination of affected neurons.Compounds that effectively reduce GPR17 receptor activity can meet these requirements.

[0012] However, few compounds that effectively modulate GPR17 activity are known.

[0013] WO2005 / 103291 suggests the endogenous molecules 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG) as activating ligands for GPR17, discloses the analgesic effects of GPR17 agonists, and proposes the use of GPR17 agonists to treat neuropathic pain and as tools in GPR17 screening assays. However, the reported affinities of 5-ALA and PBG are very low, and the amounts required for the assays are significant; that is, in the three-digit micromolar range for 5-ALA and even in the mM range for PBG, making both compounds poorly suited for routine screening assays or even for therapeutic use. Moreover, PBG is a chemically unstable reactive compound that degrades rapidly on exposure to air and light, making its routine handling impractical. Thus, these compounds do not provide a promising starting point for developing therapeutically effective negative GPR17 modulators.

[0014] Montelukast and pranlukast were originally developed as leukotriene receptor antagonists and were recently found to also act on the GPR17 receptor (Ciana et al., EMBO J. 2006, 25, 4615-4627). However, subsequent results of functional assays were contradictory, with montelukast (Hennen et al., 2013, ibid.), whereas pharmacological inhibition of GPR17 with pranlukast promoted differentiation of primary mouse (Hennen et al., 2013, ibid.) and rat (Ou et al., J. Neurosci. 36, 2016, 10560-10573) oligodendrocytes. Pranlukast phenocopies the effects of GPR17 inhibition in the lysolecithin model of focal demyelination, as both GPR17 knockout and pranlukast-treated wild-type mice show early onset of remyelination (Ou, supra). These results strongly support the hypothesis that GPR17 inhibitors offer a potential treatment for human demyelinating diseases.

[0015] However, the affinity of Monteclast and Planclast for GPR17 is only in the high micromolar range (Koese et al, ACS Med. Chem. Lett. 2014, 5, 326-330). Given the high protein binding and poor brain penetration of both compounds, it is unlikely that they will reach high enough free concentrations to bind to the GPR17 receptor in amounts suitable for human therapy. Furthermore, results obtained in vivo with these compounds are difficult to interpret due to their confounding high affinity for the CYSLT1 receptor. Cross-reactivity to other receptors further complicates their use to target GPR17.

[0016] US Patent No. 8,623,593 discloses certain indole-2-oxolinic acids as GPR17 agonists and their use in screening assays. However, all of these derivatives are strong agonists and are not suitable for downregulating GPR17 activity, which is necessary for the treatment of myelination disorders such as MS. Moreover, this class of GPR17 activators does not cross the blood-brain barrier well due to the easily ionized oxol group, and therefore was not a suitable lead compound for developing negative GPR17 modulators. See also Baqi et al., Med.Chem.Commun., 2014, 5, 86 and Koese et al., 2014, ibid.

[0017] WO2013 / 167177 suggests certain phenyltriazole and benzodiazepine compounds as GPR17 antagonists. However, the disclosed compounds were selected solely based on the results of in silico screening, and no biological data was provided. The inventors of the present application have not been able to confirm the GPR17 antagonistic modulation activity of any of the ligands purportedly proposed by the authors of this previous patent application.

[0018] WO2018 / 122232 discloses (Aaza) indole-benzothiophene- and benzofuran-3-sulfonamides as potent GPR17 antagonists. However, all of the disclosed compounds have an indole moiety with an unsubstituted nitrogen, and therefore differ from the compounds of the present application, which always have N-substitution at the indole group. Thus, the present application provides potent GPR17 modulators that surprisingly offer additional structural options by allowing the nitrogen of the indole ring to be substituted with various residues with or without polar groups. Summary of the Invention

[0019] Description of the Invention The present invention relates to compounds that act as negative modulators of the GPR17 receptor. In a preferred embodiment, the compounds act as negative agonists of the GPR17 receptor, thus inhibiting constitutively active GPR17.

[0020] The present application relates to a compound having formula I [ka] During the ceremony X1 is N or =C(R7)-; X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C 1‐6 Alkyl, C 3‐5 Cycloalkyl and C 3‐5 heterocycloalkyl, each of which is selected from halogen, hydroxy, oxo, azido, cyano, carboxy, and C 1‐3 Optionally substituted with one or more substituents selected from alkoxy, 1‐3 ) the alkoxy can be unsubstituted or substituted with one or two groups selected from halogen, oxo, hydroxy, and carboxy; R2 is hydrogen or fluoro, preferably hydrogen; R4 is hydrogen or fluoro, preferably hydrogen; R5 is hydrogen or halogen, preferably hydrogen; R6 is halogen, cyano, cyclopropyl, C 1‐3 Alkyl, and C 1‐3 alkyloxy, wherein cyclopropyl, alkyl, or alkyloxy may be optionally substituted with one or more fluorine atoms; R7 is hydrogen, halogen, C 1‐2 Alkyl, Fluoro C 1‐2 Alkyl, C 1‐2 Alkoxy, Fluoro C 1‐2 selected from alkoxy, cyclopropyl and cyclopropyloxy; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is halogen, cyano, cyanomethyl, cyclopropyl, and halogen, C 1‐3 Alkyloxy and Fluoro(C 1‐3 ) alkyloxy, 1‐3 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and their pharma- ceutically acceptable salts, solvates, isotopes and co-crystals.

[0021] In one preferred embodiment, in the compound of formula I, X2 and X3 are not both nitrogen at the same time. In one preferred embodiment, X3 is N and X2 is C(R12).

[0022] Preferably, in the compounds of the present disclosure, R is C 1‐5 Alkyl or C 3‐4 Cycloalkyl, even more preferably C 1‐4 Alkyl or C 1‐3 alkyl, each of which is selected from halogen, hydroxy, oxo, azido, cyano, carboxy, and C 1‐3 alkoxy, wherein the (C 1‐3 ) Alkoxy can be unsubstituted or substituted with one, two or three groups selected from halogen, preferably fluoro, oxo, carboxy and hydroxy. In one preferred embodiment, R1 is an unsubstituted methyl-substituted C 1‐4 Alkyl and substituted C 1‐3 and alkyl, wherein the alkyl substituents are preferably fluoro, chloro, hydroxy, carboxy, hydroxy (C 1‐2 )Alkoxy, Fluoro(C1‐2 ) 1, 2, 3 or 4 substituents selected from alkoxy and fluorohydroxyethoxy.

[0023] In another preferred embodiment, R1 is unsubstituted or selected from fluoro, hydroxy, carboxy, and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, carboxy and hydroxy, with the alkoxy substituent being preferably hydroxy.

[0024] In another preferred embodiment, R is unsubstituted methyl or C 1‐3 alkyl, the latter being unsubstituted or selected from fluoro, hydroxy, and C 1‐2 alkoxy, wherein C 1‐2 The alkoxy is further substituted with one or more substituents selected from fluoro and hydroxy.

[0025] In another preferred embodiment, R is C 1‐3 and alkyl, which is optionally substituted with from 1 to 4 substituents selected from fluoro, hydroxy, carboxy, hydroxymethoxy and hydroxyethoxy.

[0026] In another preferred embodiment, R1 is selected from the group: hydroxyethyl, hydroxypropyl, carboxymethyl, fluorohydroxypropyl, fluoroethyl, methyl and hydroxyethoxyethyl.

[0027] In another preferred embodiment, R1 is selected from the group: monohydroxyethyl, monohydroxypropyl, dihydroxypropyl, monocarboxymethyl, fluoromonohydroxypropyl, fluoroethyl, methyl and hydroxyethoxyethyl.

[0028] In a preferred embodiment, R2 and R4 are both hydrogen. In another preferred embodiment, R2, R4 and R5 are all hydrogen.

[0029] In one preferred embodiment, R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl. In another preferred embodiment, R6 is selected from fluoro, chloro, bromo, fluoromethyl and fluoromethoxy. In another preferred embodiment, R6 is halogen, preferably fluoro, chloro or bromo.

[0030] In one preferred embodiment, R7 is hydrogen.

[0031] One embodiment is a compound of formula I, wherein X1 is N or =C(R7)-; X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, oxo, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2 is hydrogen or fluoro, preferably hydrogen; R4 is hydrogen or fluoro, preferably hydrogen; R5 is hydrogen or fluoro, preferably hydrogen; R6 is selected from halogen, cyano, cyclopropyl, methyl, and methoxy, where methyl or methoxy can be optionally substituted with one or more fluorine atoms; R7 is hydrogen, halogen, methyl, fluoroC 1‐2 Alkyl, C 1‐2 Methoxy, Fluoro C 1‐2 is selected from alkoxy, cyclopropyl and cyclopropyloxy, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is halogen, cyano, cyanomethyl, cyclopropyl, and halogen, C 1‐3 Alkyloxy and Fluoro(C 1‐3 ) alkyloxy; 1‐3 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; wherein preferably, X2 and X3 are not both nitrogen at the same time; Regarding.

[0032] One embodiment is a compound of formula I, X1 is N or =C(R7)-; X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, methyl, and methoxy, where methyl or methoxy can be optionally substituted with one or more fluorine atoms; R7 is selected from hydrogen, fluoro and chloro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is halogen and fluoro, C 1‐2 Alkyloxy and Fluoro(C 1‐2 ) alkyloxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; wherein preferably, X2 and X3 are not both nitrogen at the same time; Regarding.

[0033] One embodiment is a compound of formula I, X1 is N or =C(R7)-; X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; wherein preferably, X2 and X3 are not both nitrogen at the same time; About

[0034] One embodiment of the disclosure is a compound according to formula I, where X2 is =C(R12)- and X3 is N, the compound having formula Ia: [ka] During the ceremony X1 is N or -C(R7)-; R1 is C 1‐3 Alkyl or C 3‐4 Cycloalkyl, preferably C 1‐3 alkyl, each of which is selected from the group consisting of halogen, hydroxy, methoxy, oxo, carboxy, azido, cyano, fluoro (C 1‐2 )Alkoxy and hydroxy (C 1‐3 )alkoxy, preferably fluoro, chloro, hydroxy, oxo, and hydroxy (C 1‐2 ) alkoxy, where R1 is preferably C 1‐3 alkyl, which is unsubstituted or selected from fluoro, hydroxy, carboxy and C 1‐2 alkoxy; 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from fluoro, carboxy and hydroxy, preferably from fluoro and hydroxy. R2, R4, and R5 are all hydrogen. R6 is halogen, cyclopropyl, cyano, C 1‐3 Alkyl, and C 1‐3alkyloxy, any alkyl or alkyloxy being optionally substituted with one or more fluorine atoms; R7 is selected from hydrogen, fluoro, chloro, fluoromethyl and fluoromethoxy, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably fluoro or methoxy; R10 is halogen, cyano, and halogen, C 1‐2 Alkyloxy and fluoro(C 1‐2 ) alkyloxy; 1‐3 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0035] One embodiment is a compound of formula Ia, X1 is N or -C(R7)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen or fluoro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably fluoro; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0036] In one preferred embodiment, in the compound of formula Ia, X1 is N or =C(R7)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R4 are all hydrogen; R6 is chloro or difluoromethyl, preferably chloro; R7 is hydrogen; R8 is fluoro or methoxy, preferably methoxy; R10 is selected from fluoro, chloro, bromo, fluoromethoxy, fluoroethoxy, methoxyethoxy, and fluoromethoxyethoxy; R11 is fluoro; R12 is fluoro or hydrogen, preferably hydrogen.

[0037] One embodiment is a compound according to formula I where X2 is -C(R12)- and X3 is =C(R9)-, the compound having formula Ib: [ka] During the ceremony X1 is N or -C(R7)-; R1 is C 1‐3 Alkyl or cyclo(C 3‐4 ) alkyl, preferably C 1‐3alkyl, each of which is optionally selected from halogen, hydroxy, methoxy, oxo, carboxy, azido, cyano, and hydroxy (C 1‐3 ) alkoxy, preferably fluoro, chloro, hydroxy, carboxy, and hydroxy (C 1‐2 ) alkoxy, preferably R1 is unsubstituted or is selected from fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is halogen, cyclopropyl, cyano, C 1‐3 Alkyl, and C 1‐3 alkyloxy, any alkyl or alkyloxy being optionally substituted with one or more fluorine atoms; R7 is selected from hydrogen, fluoro, chloro, fluoromethyl and fluoromethoxy, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is halogen, halogen, C 1‐2 Alkyloxy and Fluoro(C 1‐2 ) alkyloxy; 1‐3 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0038] One embodiment is a compound of formula Ic, X1 is N or =C(R7)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably fluoro; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0039] One embodiment is a compound of formula Ic, X1 is N or =C(R7)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro and fluoromethyl, preferably chloro; R7 is hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably fluoro; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0040] One embodiment is a compound according to formula I where R2 is N and X3 is =C(R9)-, the compound having formula Ic: [ka] During the ceremony X1 is N or -C(R7)-; R1 is C 1‐3 Alkyl or cyclo(C 3‐4 ) alkyl, preferably C 1‐3 alkyl, each of which is optionally selected from halogen, hydroxy, methoxy, oxo, carboxy, azido, cyano, and hydroxy (C 1‐3 )alkoxy, preferably fluoro, chloro, hydroxy, oxo, and hydroxy (C 1‐2 ) alkoxy, where preferably R1 is unsubstituted or is selected from fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 alkyl, where C1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is halogen, cyano, cyclopropyl, C 1‐3 Alkyl, and C 1‐3 alkyloxy, any alkyl or alkyloxy optionally being substituted with one or more fluorine atoms; R7 is selected from hydrogen, fluoro, chloro, fluoromethyl, and fluoromethoxy; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is halogen, cyano, and halogen, C 1‐2 Alkyloxy and Fluoro(C 1‐2 ) alkyloxy; 1‐3 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0041] One embodiment is a compound of formula Ic, X1 is N or =C(R7)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, carboxy, hydroxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0042] In one embodiment, R is C 1‐3 This relates to a compound according to any of the above formulae I, Ia, Ib or Ic, wherein R is alkyl, which is optionally substituted with one or two substituents selected from hydroxy, carboxy, fluoro, fluoromethoxy, fluoroethoxy, hydroxymethoxy and hydroxyethoxy.

[0043] In one embodiment, R is C 1‐3 This relates to a compound according to any of the above formulae I, Ia, Ib or Ic, wherein R is alkyl, which is optionally substituted with one or two substituents selected from hydroxy, carboxy, fluoro, hydroxymethoxy and hydroxyethoxy.

[0044] In one embodiment, R is selected from the group consisting of methyl, carboxymethyl, hydroxymethyl, carboxyethyl, hydroxyethyl, hydroxypropyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorohydroxyethyl, fluorohydroxypropyl, and hydroxy(C 1‐2 )Alkoxy(C 1‐2 ) alkyl.

[0045] In one embodiment, R1 is preferably selected from monohydroxyethyl, dihydroxypropyl, fluoroethyl, and mono-, di-, or trifluoromonohydroxypropyl.

[0046] One embodiment relates to a compound according to any of the above formulas I, Ia, Ib or Ic, wherein R6 is selected from fluoro, chloro, bromo, cyano, methyl, methoxy, fluoromethyl and fluoromethoxy, cyclopropyl and isopropyl. In one preferred embodiment, R6 is chloro. In another preferred embodiment, R6 is fluoromethyl.

[0047] One embodiment relates to a compound according to any of the above formulae I, Ia, Ib or Ic, wherein R10 is selected from fluoro, chloro, bromo, fluoromethoxy, fluoroethoxy, fluoromethoxyethoxy, fluoroethoxymethoxy and fluoroethoxyethoxy. Preferably, R10 is selected from bromo, chloro, difluoromethoxy and difluoroethoxy.

[0048] One embodiment relates to a compound according to any of the above formulae I, Ia, Ib or Ic, wherein R7 is hydrogen.

[0049] One preferred embodiment relates to compounds according to any of the above formulae I, Ia, Ib or Ic, wherein R2, R4, R5 and R7 are all hydrogen.

[0050] One embodiment relates to a compound according to formula I, where X is N, and therefore has formula II: [ka] wherein R1, R2, R4, R5, R6, R10, R11, X2, and X3 are as described for compounds of formula I above (including compounds of subformulae Ia, Ib, or Ic), and preferably X2 and X3 are not both nitrogen.

[0051] In one embodiment, in the compound of formula II: X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C 1‐3 alkyl, which is unsubstituted or is selected from the group consisting of fluoro, hydroxy, carboxy, C 1‐2 Alkoxy, hydroxy (C 1‐2 ) alkoxy and fluoro(C 1‐2 ) alkoxy; R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl, preferably from fluoro, chloro and fluoromethyl; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Preferably, X2 and X3 are not both nitrogen.

[0052] In one embodiment, the compound has formula IIa, IIb, or IIc, respectively. [ka] wherein R1, R2, R4, R5, R6, R9, R10, R11, and R12 are as described above for compounds of formula I (including compounds of sub-formulas Ia, Ib, or Ic).

[0053] One embodiment is a compound of formula IIA, IIb or IIc, R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl, preferably selected from fluoro, chloro, bromo and fluoromethyl; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy and fluoromethoxy; 1‐2 alkyloxy, R10 is preferably selected from fluoro, chloro, bromo, fluoromethoxy and fluoroethoxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0054] One embodiment is a compound of formula IIA, IIb or IIc, R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro and fluoromethyl, preferably from chloro and fluoromethyl; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy and fluoromethoxy; 1‐2 alkyloxy, R10 is preferably selected from fluoro, chloro, bromo, fluoromethoxy and fluoroethoxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0055] One embodiment relates to a compound according to formula I where X is -C(R7)-, the compound having formula III: [ka] wherein R1, R2, R4, R5, R6, R10, R11, X2, and X3 are as described for compounds of formula I, and preferably, X2 and X3 are not both nitrogen.

[0056] One embodiment is a compound of formula III, X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl, preferably selected from fluoro, chloro, bromo and fluoromethyl; R7 is hydrogen, fluoro or chloro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and their pharma- ceutically acceptable salts, solvates, isotopes and co-crystals, Preferably, X2 and X3 are not both nitrogen at the same time.

[0057] One embodiment is a compound of formula III, X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen, fluoro or chloro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; 1‐2 alkyloxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and their pharma- ceutically acceptable salts, solvates, isotopes and co-crystals, Preferably, X2 and X3 are not both nitrogen at the same time.

[0058] One embodiment relates to compounds having formula IIIa, IIIb or IIIc, respectively. [ka] R1, R2, R4, R5, R6, R10, R11, R9, and R12 are as described above.

[0059] One embodiment is a compound having formula IIIa, IIIb or IIIc, R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl, preferably selected from fluoro, chloro, bromo and fluoromethyl; R7 is hydrogen, fluoro or chloro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy and fluoromethoxy; 1‐2 alkyloxy, R10 is preferably selected from fluoro, chloro, bromo, fluoromethoxy and fluoroethoxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0060] One embodiment is a compound having formula IIIA, IIIb or IIIc, R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C 1‐2 C substituted with one or more substituents independently selected from alkoxy 1‐3 Alkyl, C 1‐2 Alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, preferably fluoro and hydroxy; R2, R4, and R5 are all hydrogen; R6 is selected from fluoro, chloro, and fluoromethyl; R7 is hydrogen, fluoro or chloro, preferably hydrogen; R8 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R9 is hydrogen or fluoro, preferably hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy and fluoromethoxy; 1‐2 alkyloxy, R10 is preferably selected from fluoro, chloro, bromo, fluoromethoxy and fluoroethoxy; R11 is selected from hydrogen, fluoro and methoxy, preferably from fluoro and methoxy; R12 is hydrogen or fluoro, preferably hydrogen; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0061] One preferred embodiment is a compound disclosed herein, wherein R1 is C 1‐3 Alkyl and (C 1‐2 )Alkoxy(C 1‐2 ) alkyl, each of which is optionally substituted with 1 to 4 substituents selected from hydroxy and fluoro; R2, R4, R5, R7 (if R7 is present), R9 and R12 are all hydrogen; R6 is selected from fluoro, chloro, bromo, fluoromethoxy and fluoromethyl, preferably chloro or bromo; R8 is selected from fluoro and methoxy; R10 is halogen and fluoro(C 1‐3 ) alkoxy; R11 is fluoro or methoxy; and pharma- ceutically acceptable salts, solvates, isotopes and co-crystals thereof; Regarding.

[0062] One preferred embodiment relates to a compound selected from the following group: N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)indole-3-sulfonamide 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3,3,3-trifluoro-2-hydroxypropyl)indole-3-sulfonamide 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)indole-3-sulfonamide 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,3-dihydroxypropyl)indole-3-sulfonamide 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-methylindole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2,3-dihydroxypropyl)indole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxypropyl)indole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-[2-(2-hydroxyethoxy)ethyl]indole-3-sulfonamide 6-Chloro-N-[6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl]-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-fluoroethyl)indole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)indole-3-sulfonamide 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylindole-3-sulfonamide 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-hydroxyethyl)indole-3-sulfonamide N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylindole-3-sulfonamide 2-[3-[(4-bromo-2,5-difluorophenyl)sulfamoyl]-6-chloroindol-1-yl]acetic acid, and N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)indole-3-sulfonamide.

[0063] Another embodiment relates to any of the "exemplary compounds" I-1 to I-36 specifically disclosed herein.

[0064] Another preferred embodiment is a compound having the structure of formula I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb or IIIc, or any of the compounds specifically disclosed herein having at least one 18It relates to compounds containing an F isotope, preferably at the position of the fluorine atom shown in one of the compounds disclosed herein. As a non-limiting example, in the compound 6-chloro-N-(6-chloro-2,5-difluoropyridin-3-yl)-1H-indole-3-sulfonamide disclosed herein, at least one of the two fluorines is 18 F isotope. This is equally true for other fluorine-containing compounds described herein. These 18 F-containing compounds can preferably be used as PET tracers.

[0065] Another preferred embodiment is a compound having the structure of formula I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb or IIIc, or any of the compounds specifically disclosed herein having at least one 11 C isotopes are preferably included at the carbon atoms as indicated herein. 11 The C-containing compound can preferably be used as a PET tracer.

[0066] Another preferred embodiment is a compound having the structure of formula I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb or IIIc, or any of the compounds specifically disclosed herein having at least one 123 I, 125 I or 131 It relates to compounds containing an I isotope, preferably at the position of the iodine atom as shown herein. As a non-limiting example, in the compound 6-chloro-N-(6-iodopyridin-3-yl)-1H-indole-3-sulfonamide disclosed herein, the iodine is 123 I, 125 I, or 131 It can be represented by the I isotope. 123 I, 125 I or 131 Compounds containing I can be preferably used as SPECT tracers.

[0067] Therapeutic and diagnostic applications In one aspect, the invention relates to any of the compounds described herein for use in therapy or diagnosis, particularly in the treatment of animals, especially humans.

[0068] Due to their GPR17 modulating properties, the compounds of the invention can be used as medicines and can be used for the treatment and / or prevention of various diseases of the CNS system.

[0069] Thus, one embodiment of the present disclosure is a compound as described herein for use as a medicament, in particular for use as a medicament for the treatment and / or prevention of a GPR17 related disease.

[0070] GPR17-related diseases or disorders are diseases associated with dysfunction of the GPR17 signaling system, such as overexpression and / or overactivity of the GPR17 receptor. Without wishing to be bound by theory, the activity of GPR17 may increase, expand, or otherwise change in certain tissues, such as oligodendrocyte precursor cells (OPCs), or during oligodendrocyte maturation, potentially to activate endogenous stimuli, such as inflammatory factors. High activity of GPR17 may impede oligodendrocyte differentiation and efficient myelination, promoting the emergence or further development of myelination disorders (see Chen et al., supra). Thus, negative GPR17 modulators may promote myelination by reducing or turning off GPR17 activity and by supporting OPC maturation into myelin-producing oligodendrocytes (see, e.g., Simon et al., supra).

[0071] In a preferred aspect, the present invention relates to any of the compounds described herein for use in the diagnosis, prevention or treatment of disorders or syndromes selected from and / or related to myelination disorders, particularly demyelinating disorders such as disorders of the central nervous system. In one embodiment, the compounds of the present invention are for use in promoting, stimulating and / or accelerating remyelination in an animal in need thereof. In one embodiment, remyelination associated with administration of the compounds of the present invention will prevent or treat a demyelinating disease, such as, but not limited to, multiple sclerosis.

[0072] The compounds of the invention may also be useful in the treatment or prevention of disorders or syndromes associated with brain tissue injury, cerebrovascular disorders, and certain neurodegenerative diseases.

[0073] Neurodegenerative disorders have recently been strongly associated with loss of myelination. Thus, preserved oligodendroglial and myelin function is considered to be an important prerequisite for preventing axonal and neuronal degeneration (see, for example, Ettle et al., supra). Thus, negative GPR17 modulators may represent a good therapeutic option for any neurodegenerative disease associated with demyelination and / or affected myelination, such as ALS, MSA, Alzheimer's disease, Huntington's disease, or Parkinson's disease.

[0074] Thus, in certain preferred aspects, the compounds of the invention can be used for the prevention and / or treatment of peripheral or central myelination disorders, particularly myelination disorders of the central nervous system. In one aspect, the compounds of the invention are used in the treatment and / or prevention and / or diagnosis of myelination disorders by oral administration. In a preferred embodiment, the myelination disorder treated with the compounds of the invention is a demyelinating disorder.

[0075] Examples of such myelination disorders to be treated and / or prevented by the presently disclosed compounds are, inter alia: - Multiple sclerosis (MS), including its various subforms; - Neuromyelitis optica (also known as Devic's disease), - chronic relapsing inflammatory optic neuritis, acute disseminated encephalomyelitis, - Acute hemorrhagic leukoencephalitis (AHL), - Periventricular leukomalacia - demyelination due to viral infections, e.g. HIV or progressive multifocal leukoencephalopathy, - central pontine myelinolysis and extrapontine myelinolysis, - demyelination due to traumatic brain tissue injury, including compression demyelination, e.g. due to a tumor; - demyelination in response to hypoxia, stroke, ischemia, or other cardiovascular diseases, -Demyelination due to exposure to carbon dioxide, cyanide, or other central nervous system toxins - Schilder's disease, - Baroconcentric sclerosis, - perinatal encephalopathy, and - Neurodegenerative diseases, especially: o Amyotrophic lateral sclerosis (ALS). o Alzheimer's disease (AD). oMultiple system atrophy Parkinson's disease Spinocerebellar ataxia (SCA), also known as spinocerebellar atrophy Huntington's disease - Psychiatric disorders such as schizophrenia and bipolar disorder (see, for example, Fields, Trends Neurosci 31, 2008, 361; Tkachev et al, Lancet 362, 2003, 798). - peripheral myelinating disorders such as leukodystrophies, peripheral demyelinating neuropathies, Dejerine-Sottas syndrome, or Charcot-Marie-Tooth disease

[0076] Treatment or prevention of a central nervous system disease, such as a demyelinating disease, also includes treatment of the signs and symptoms associated with such disease.

[0077] For example, the use of the compounds of the invention for the treatment and / or prevention of MS also includes the treatment and / or prevention of signs and symptoms associated with MS, such as adverse effects on the optic nerve (loss of vision, double vision), spinal column (loss of sensation), corticospinal tract (spastic weakness), cerebellar pathways (loss of coordination, dysarthria, dizziness, cognitive impairment), medial longitudinal fasciculus (double vision in lateral gaze), spinal trigeminal tract (facial numbness or pain), muscle weakness (dysphagia, bladder or bowel control, spasms), or psychological effects associated with the underlying disease, such as depression, anxiety or other mood disorders, general weakness or insomnia.

[0078] Thus, the compounds of the present invention are for use in treating the signs and symptoms of myelinating diseases, particularly demyelinating diseases such as multiple sclerosis. Such signs and symptoms of MS include, but are not limited to, the following groups: vision loss, blurred vision, double vision, loss or impairment of sensation, weakness such as spastic weakness, impaired motor coordination, dizziness, cognitive impairment, facial numbness, facial pain, impaired swallowing, impaired speech, impaired bladder and / or bowel control, convulsions, depression, anxiety, mood disorders, insomnia, and fatigue.

[0079] In one preferred embodiment, the compound of the present invention is for use in treating multiple sclerosis. MS is a heterogeneous myelinating disease and can present in a variety of different forms and stages, including but not limited to relapsing-remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS, each of which depends on the activity and progression of the disease. Thus, in one embodiment, the compound of the present invention is for use in treating multiple sclerosis in its various stages and forms, as described herein.

[0080] In one aspect, the compounds of the invention are for use in the treatment and / or prevention of neuromyelitis optica (also known as Devic's disease or Devic's syndrome). Neuromyelitis optica is a complex disorder characterized by inflammation and demyelination of the optic nerve and spinal cord. Many of the associated symptoms are similar to MS, including muscle weakness, especially in the hands and feet, loss of sensation, and loss of bladder control.

[0081] In one aspect, the compounds of the invention are for use in the prevention and / or treatment of ALS, which has recently been associated with increased oligodendrocyte degeneration and demyelination, suggesting that ALS is a target disease for negative GPR17 modulators (Kang et al., supra; Fumagalli et al., Neuropharmacology 104, 2016, 82).

[0082] In one aspect, the compounds of the invention are for use in the prevention and / or treatment of Huntington's disease, which is well described as being associated with affected myelination (Bartzokis et al., supra; Huang et al., Neuron 85, 2015, 1212).

[0083] In one aspect, the compounds of the invention are for use in the prevention and / or treatment of multiple system atrophy. MSA has recently been strongly linked to demyelination (Ettle supra; Jellinger supra), suggesting a remyelination strategy to treat or prevent MSA.

[0084] In one embodiment, the compounds of the present invention are for use in the prevention and / or treatment of Alzheimer's disease. AD has recently been observed to be associated with increased oligodendronecytic cell death and focal demyelination, which represent the pathological process of AD (Mitew et al., Acta Neuropathol 119, 2010, 567).

[0085] One aspect of the invention relates to a method for treating any of the diseases or disorders described herein, particularly myelination diseases such as MS, neuromyelitis optica, ALS, Huntington's chorea, Alzheimer's disease, etc., by administering to a subject, including a human patient, in need of treatment a therapeutically effective amount of a compound of the invention.

[0086] In another aspect, the compounds of the present invention can be used for the prevention and treatment of spinal cord injury, perinatal encephalopathy, stroke, ischemia, or cerebrovascular accidents.

[0087] In one aspect, the present invention relates to a method for the prevention and / or treatment of disorders associated with impaired myelination, or disorders or syndromes associated with brain tissue damage, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as described herein. A patient in need of such treatment may be any patient who has suffered brain tissue damage, such as by mechanical, chemical, viral, or other trauma.

[0088] In one aspect, the present invention relates to a method for the prevention and / or treatment of disorders of myelination or syndromes or disorders associated with stroke or other disorders or syndromes associated with cerebral ischemia, comprising administering a therapeutically effective amount of a compound as described herein to a patient in need thereof. The patient in need thereof may be any patient who has recently experienced cerebral ischemia / stroke, which may have been caused, for example, by occlusion of a cerebral artery, either by embolism or local thrombosis.

[0089] GPR17 has also recently been associated with food intake, insulin regulation, and obesity. According to various reports, negative modulators of GPR17 may be useful in controlling food intake and treating obesity (see, for example, Ren et al, Diabetes 64, 2015;3670). Thus, one embodiment of the present invention relates to the use of the compounds herein for the prevention and / or treatment of obesity, as well as methods of treating obesity.

[0090] Furthermore, the compounds of the present invention can be used for the prophylactic treatment of tissues in which GPR17 is expressed, such as the heart, lungs, or kidneys. In one embodiment, the compounds of the present invention can be used to treat or prevent ischemic damage to the kidney and / or heart.

[0091] GPR17 has also been implicated in lung inflammation and asthma, such as that induced by dust mites (Maekawa, J Immunol 2010, 185(3), 1846-1854). Thus, the compounds of the present invention can be used to treat asthma or other lung inflammation.

[0092] Treatment according to the invention may involve administration of one of the compounds disclosed herein as a "stand-alone" treatment for a CNS disease, particularly a myelination disease or disorder such as MS or ALS. Alternatively, the compounds disclosed herein may be administered together with other useful drugs in a combination therapy.

[0093] In a non-limiting example, the compound according to the invention is combined with another drug for treating a myelination disorder such as MS, having a different mechanism of action, such as an anti-inflammatory drug or an immunosuppressant. For example, such compounds include (i) a corticosteroid, such as prednisone, methylprednisone or dexamethasone, (ii) a beta interferon, such as interferon beta-1a, interferon beta-1b or pegylated interferon beta-1a, (iii) an anti-CD20 antibody, e.g., ocrelizumab. (iv) glatiramer salts, such as glatiramer acetate, (v) dimethyl fumarate, (vi) fingolimod and other sphingosine-1-phosphate receptor modulators, such as ponesimod, siponimod, ozanimod or laquinimod, (vii) dihydro-orotate dehydrogenase inhibitors, such as teriflunomide or leflunomide, (viii) anti-integrin alpha 4 antibodies, such as natalizumab, (ix) anti-CD52 antibodies, such as alemtuzumab, (x) mitoxantrone, (xi) anti-Lingo1 antibodies, such as opicinumab, or (xii) other immunomodulatory therapies, such as masitinib.

[0094] Similarly, the compounds of the present invention can be combined with analgesics when treating painful myelination conditions, and the compounds of the present disclosure can be used in combination with antidepressants to simultaneously treat the psychological effects associated with the underlying myelination disorder being treated.

[0095] In combination therapy, two or more active principles can be provided via the same formulation or as a "kit of parts", i.e. in separate galenic formulation units.Also, two or more active ingredients, including the compound of the present invention, can be administered to a patient simultaneously or subsequently, for example, in interval therapy.The additional drug can be administered by the same administration mode or different administration modes.For example, the GPR17 modulator of the present invention can be administered orally, while the second drug can be administered by subcutaneous injection.

[0096] In one aspect, the compounds of the present invention can be used for the diagnosis and / or monitoring of GPR17 related diseases as further described herein, in particular demyelinating diseases as disclosed herein, preferably in the diagnosis and monitoring of multiple sclerosis.

[0097] In one aspect, the compounds of the invention can be used to diagnose and / or monitor the expression, distribution and / or activation of GPR17 receptor in vivo, e.g., directly in a subject, e.g., using molecular imaging techniques, or in vitro, e.g., by examining a sample such as a body fluid or tissue taken from a subject. Such determination of GPR17 activity, expression and / or distribution can be used to predict, diagnose and / or monitor (a) the status and progression of GPR17-related disorders as described herein, particularly myelination disorders, e.g., including but not limited to multiple sclerosis, and (b) the efficacy and / or applicability and / or appropriate dosing of treatments associated with such GPR17-related disorders.

[0098] In one aspect, the compounds of the present invention can be used as PET or SPECT tracers, as further disclosed herein, to perform in vivo diagnosis and / or disease monitoring.Thereby, the expression, activation and / or distribution of GPR17 receptor can be measured directly in a subject, for example by imaging a human patient after administration of the GPR17 PET or SPECT tracer of the present invention.This can be used to facilitate proper diagnosis of disease, help determine applicable treatment options, and / or to monitor disease progression, and / or to monitor or predict the success of medical intervention, including the selection of therapeutic agents and their appropriate administration and / or dosage.

[0099] In one embodiment, the PET or SPECT tracers of the present invention can be used in combination with a therapeutic agent, i.e., as a companion diagnostic, to monitor and / or predict the efficacy and / or safety of a therapeutic agent in a particular subject, or to estimate appropriate dosages of a pharmaceutical agent.

[0100] One embodiment relates to a PET or SPECT tracer of the invention for use as a companion drug in combination with a therapeutic agent. The therapeutic agent used with the PET or SPECT tracer of the invention may be selected from the group of: (a) an unlabeled compound of the invention, (b) a GPR17 modulating compound different from the compound of the invention, and (c) a drug for the treatment of myelination disorders, including but not limited to a drug for use in the treatment of multiple sclerosis, which is not a GPR17 modulator, as further described herein.

[0101] One embodiment relates to a kit comprising: (a) as a first component, a PET or SPECT tracer of the present invention, in particular having a structure according to any of formulas I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb and IIIc, as further defined herein, or having the structure of any one of the compounds disclosed herein, but containing at least one radionuclide suitable for PET or SPECT imaging, preferably 18 F, 11 C. 123 I, 125 I and 131 PET or PET tracers based on compounds incorporating a radionuclide selected from I; (b) as a second component, a therapeutic agent selected from the following: i. Compounds of the present invention having a structure according to any of formulas I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb and IIIc, as further defined herein, or any of the individual compounds disclosed herein, and having no incorporated radioactive nuclide; ii. A GPR17 modulating compound different from the compound of the invention defined under (i), and iii. Drugs for the treatment of myelination diseases that do not have GPR17 modulating activity, including but not limited to drugs for use in treating multiple sclerosis; such compounds are known to those skilled in the art including those examples further described above.

[0102] Alternatively, the compounds of the invention can be used in in vitro diagnostic assays, for example to test a suitable body fluid of a subject, such as blood, plasma, urine, saliva, or cerebrospinal fluid, for any level of GPR17 expression, activity, and / or distribution.

[0103] One embodiment relates to a method for treating a GPR17-related disease, in particular a myelination disease, including but not limited to multiple sclerosis, comprising the steps of: (a) determining the expression, activity and / or distribution of GPR17 receptor in a subject, (b) comparing the expression, activity and / or distribution of GPR17 receptor in said subject with the expression, activity and / or distribution of GPR17 receptor in one or more healthy subjects or populations, (c) determining the need for drug therapy or prophylaxis in said subject based on the deviation of GPR17 expression, activity and / or distribution in said subject from healthy subjects or populations, and (d) treating the subject with deviation of GPR17 receptor expression, activity and / or distribution by administering to said individual a therapeutic agent, wherein the agent is suitable for treating a GPR17-related disease or disorder, in particular by administering a GPR17 modulator, preferably by administering one or more of the compounds of the invention. In one embodiment, the determination (a) of the expression, activity and / or distribution of GPR17 is carried out using one of the compounds of the invention, in particular using a PET or SPECT tracer, or by in vitro examination of body fluids or tissues of said subject using a PET or SPECT tracer of the invention.

[0104] In one preferred embodiment, the present invention relates to a pharmaceutical composition comprising a compound described herein and a pharma- ceutically acceptable carrier.

[0105] For administration as a pharmaceutical, the compounds can be used in a pharmaceutical composition comprising the compounds of the present disclosure and a pharma- ceutically acceptable carrier, as further defined herein. Such pharmaceutical compositions can be adapted, for example, for oral, intravenous, intramuscular, subcutaneous, nasal, rectal, intracranial, ocular, buccal or transdermal administration, and can include pharma- ceutically acceptable carriers, adjuvants, diluents, stabilizers, etc.

[0106] For example, the compound of the present invention can be dissolved in oil, propylene glycol or other solvents commonly used to produce injections. Suitable examples of carriers include, but are not limited to, saline, polyethylene glycol, ethanol, vegetable oil, isopropyl myristate, etc. The compound of the present invention can be formulated into injections by dissolving, suspending or emulsifying in a water-soluble solvent such as saline or 5% dextrose, or in a water-insoluble solvent such as vegetable oil, synthetic fatty acid glyceride, higher fatty acid ester, propylene glycol, etc. The formulation of the present invention can contain any of the conventional additives such as solubilizers, isotonicity agents, suspending agents, emulsifiers, stabilizers and preservatives.

[0107] In one embodiment, the compounds of the invention can be administered orally in the form of tablets, capsules, dragees, powders, granules, or in liquid or semi-solid form, such as, but not limited to, a syrup, suspension, emulsion or solution.

[0108] Oral formulations may include, but are not limited to, sustained release agents, disintegrants, fillers, lubricants, stabilizers, antioxidants, flavorings, dispersants, electrolytes, buffers, dyes, or preservatives. Suitable excipients and formulations are known to those skilled in the art and are disclosed in standard monographs such as Remington ("The science and practice of pharmacy", Lippincott, Williams & Wilkins, 2000) or other sources familiar to those skilled in the art.

[0109] Tablets can be prepared, for example, by mixing at least one compound of the present invention with at least one non-toxic pharma- ceutically acceptable excipient, such as, for example, tableting agents, binders, fillers / diluents, disintegrants, plasticizers, etc., and any solvents (aqueous or non-aqueous), and then processing the mixture into tablets by processes including, but not limited to, dry compression, dry granulation, wet granulation, spray drying, or melt extrusion. Tablets can be uncoated or coated by known techniques to mask the bad taste of unpleasant tasting drugs or to delay disintegration and absorption of the active ingredients in the gastrointestinal tract.

[0110] Tablets can provide immediate or sustained release of the compounds of the invention.

[0111] Typical sustained release agents are those that swell upon contact with water, such as, for example, polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylcellulose, other cellulose ethers, starch, pregelatinized starch, polymethacrylates, polyvinyl acetates, microcrystalline cellulose, dextran, and mixtures thereof. Non-limiting examples of disintegrants include pregelatinized starch, sodium starch glycolate, microcrystalline cellulose, sodium oxomethylcellulose (CMC-Na), cross-linked CMC-Na, and low-substituted hydroxypropylcellulose, and mixtures thereof. Suitable fillers and binders include, but are not limited to, microcrystalline cellulose, powdered cellulose, lactose (anhydrous or monohydrate), compressible sugars, starches (e.g., corn starch or potato starch), pregelatinized starch, fructose, sucrose, dextrose, dextran, mannitol, maltitol, sorbitol, lactitol and other sugars such as saccharose, siliconized microcrystalline cellulose, calcium hydrogen phosphate, calcium hydrogen phosphate dihydrate, dicalcium phosphate dihydrate, tricalcium phosphate, calcium lactate or mixtures thereof. Lubricants, anti-adherents and / or glidants include stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oils, hydrogenated castor oil, sodium stearyl fumarate, macrogol, glycerol dibehenate, talc, corn starch, silicon dioxide, and the like, including mixtures.

[0112] The compounds of the present invention can also be formulated for parenteral administration by injection, for example, by bolus injection or infusion. Injectable compositions can be provided ready to use and can take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain excipients such as suspending, stabilizing, preservatives and / or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water or saline, before use.

[0113] For administration intranasally or by inhalation, the compounds according to the invention can be conveniently delivered in the form of an aerosol spray presentation for a pressurized pack or nebulizer using a suitable propellant, for example, dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

[0114] For ophthalmic administration, the compounds used in the present invention can be conveniently formulated as micronized suspensions in isotonic, pH-adjusted, sterile saline with or without preservatives such as bactericidal or antibacterial agents, e.g., phenylmercuric nitrate, benzylalkonium chloride, or chlorhexidine acetate. Alternatively, for ophthalmic administration, the compounds can be formulated in an ointment such as petrolatum.

[0115] For rectal administration, the compounds used in the present invention can be conveniently formulated as suppositories.These can be prepared by mixing the active ingredient with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the active ingredient.Such materials include, for example, cocoa butter, beeswax, and polyethylene glycol.

[0116] In one embodiment, the compound can be administered transdermally. This mode of administration can avoid the so-called first-pass effect of oral administration and also provide a more constant plasma level, which is particularly advantageous in some cases. The design of transdermal forms such as ointments or creams or other transdermal systems, such as patches or electrophoretic devices, is generally known in the art. See, for example, Venkatraman and Gale, Biomaterials 1998, Vol 19, p1119; Prausnitz and Langer, Nat Biotechnology 2008, Vol 26.11 p1261; WO2001 / 47503; WO2009 / 000262; WO99 / 49852; WO07 / 094876.

[0117] The preferred dosage level of the compound according to the present invention depends on various factors including the condition and weight of the patient, the severity of the specific disease, the dosage form, and the route and duration of administration, but can be appropriately selected by those skilled in the art. In various embodiments, the compound is administered in an amount ranging from 0.001 to 10 mg / kg body weight per day, or from 0.03 to 1 mg / kg body weight per day. Individual doses can range from about 0.1 to 1000 mg of active ingredient per day, about 0.2 to 750 mg / day, about 0.3 to 500 mg / day, 0.5 to 300 mg / day, or 1 to 100 mg / day. Doses can be administered once a day or in divided portions several times a day.

[0118] Another aspect of the invention is a kit comprising a pharmaceutical agent or pharmaceutical composition described herein, and instructions for its use.

[0119] definition Any reference to a compound according to the invention also includes pharma- ceutically acceptable salts, solvates, isotopes, and co-crystals of such compound, unless otherwise specified.

[0120] The term "pharmaceutically acceptable salt" relates to any salt which a compound may form and which is suitable according to the invention for administration to a subject, in particular a human subject. Such salts include those formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or with acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, These include, but are not limited to, the acid addition salts formed with organic acids such as acetic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.Other salts include 2,2-dichloroacetate, adipate, alginate, ascorbate, aspartate, 2-acetamidobenzoate, caproate, caprate, camphorate, cyclamate, lauryl sulfate, edisylate, esylate, isethionate, formate, galactarate, gentisinate, gluceptate, glucuronate, oxoglutarate, hiprate, lactobionate, napadisylate, xinafoate, nicotinate, oleate, orotate, oxalate, palmitate, embonate, and pidolaate. te), p-aminosalicylate, sebacate, tannate, rhodanide, undecylenate, etc., or salts formed when an acidic proton present in the parent compound is replaced by ammonia, arginine, benethamine, benzathine, calcium, choline, deanol, diethanolamine, diethylamine, ethanolamine, ethylenediamine, meglumine, glycine, hydrabamine, imidazole, lysine, magnesium, hydroxyethylmorpholine, piperazine, potassium, epolamine, sodium, trolamine, tromethamine, or zinc, etc.

[0121] The present invention includes within its scope solvates of the compounds defined herein. A "solvate" is a crystal formed by an active compound and a second component (solvent) that is liquid at room temperature in isolated form. Such solvates can be formed with common organic solvents, for example, hydrocarbon solvents such as benzene and toluene, chlorinated solvents such as chloroform and dichloromethane, alcoholic solvents such as methanol, ethanol, isopropanol, ether solvents such as diethyl ether or tetrahydrofuran; or ester solvents such as ethyl acetate. Alternatively, solvates of the compounds herein can be formed with water, in which case they are hydrates.

[0122] The present invention also includes within its scope co-crystals. The term "co-crystal" is used to describe a situation in which neutral molecular components are present in a crystalline compound in a well-defined stoichiometric ratio. The preparation of pharmaceutical co-crystals allows for the modification of the crystalline form of the active pharmaceutical ingredient, thereby altering its physicochemical properties without compromising its intended biological activity. Examples of co-crystal formers that may be present in a co-crystal with the active pharmaceutical ingredient include L-ascorbic acid, citric acid, glutaric acid, cinnamic acid, mandelic acid, urea and nicotinamide.

[0123] The present invention also includes all suitable isotopic variants of the compounds of the present invention. An "isotopic variant" of a compound of the present invention, or simply "isotope", is defined as one in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass than the atomic mass usually found in nature, with the most abundant isotope being preferred. Examples of isotopes that can be incorporated into the compounds of the present invention include: 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 35 S, 18 F, and 36 Specific isotopic variations of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, and chlorine, such as Cl. 3 H or 14 Those incorporating radioactive isotopes such as C are useful in drug and / or substrate tissue distribution studies. Tritiated, i.e. 3 H, and carbon 14, i.e. 14 C isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium, i.e. 2Substitution with isotopes such as H can provide certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced required dosage, and therefore may be preferred in some circumstances. Isotopic variants of the compounds of the present invention can generally be prepared by conventional procedures using appropriate isotopic variants of suitable reagents.

[0124] Also part of the invention are compounds in which at least one atom is replaced by a radioisotope of the same or a different atom that can be used in in vivo imaging techniques such as single photon emission computed tomography (SPECT) or positron emission tomography (PET).

[0125] Examples of such isotopic variants of GPR17 modulators that can be used in SPECT studies (such compounds are referred to herein as "SPECT tracers") include: 99m Tc, 111 In, 82 Rb, 137 Cs, 123 I, 125 I, 131 I, 67 Ga, 192 Ir or 201 Tl, preferably 123 I, 99m Tc or 111 For example, in order to use the compound of the present invention as a SPECT tracer, 123 I isotopes can be introduced into GPR17 modulators as disclosed herein. As a non-limiting example, to use the compounds as SPECT tracers, 123 I, 125 I and 131 A radionuclide selected from I can be incorporated into the compounds of the invention. In one embodiment, the SPECT tracers of the invention can be based on the structure of the halogen-containing GPR17 modulators disclosed herein, and can include a radionuclide selected from I. 123 I, 125 I and 131One of the I's is introduced at the position of a halogen, preferably an iodine atom.

[0126] Thus, the term "SPECT tracer of the present invention" refers to a compound having a structure according to any of formulas I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb and IIIc, as described in this patent application and further defined herein, or a compound having incorporated therein at least one radioisotope suitable for SPECT imaging, as individually disclosed herein. 99m Tc, 111 In, 82 Rb, 137 Cs, 123 I, 125 I, 131 I, 67 Ga, 192 Ir, or 201 Preferred isotopes for use in the SPECT tracers of the present invention include, but are not limited to, Tl. 123 I, 99m Tc or 111 In particular, 123 I.

[0127] Examples of GPR17 modulator derivatives (herein "PET tracers") that can be used in PET applications include: 11 C. 13 N, 15 O. 18 F, 76 Br, 124 I, 82 Rb, or 68 Ga is introduced into the compound. For example, to use the compound as a PET tracer, 18 F isotopes can be incorporated into the compounds of the invention. In one embodiment, the PET tracer can be based on the structure of a fluorine-containing GPR17 modulator disclosed herein, where the respective radionuclide 18 F is introduced in place of a fluorine atom, which replaces at least one "non-labeled" carbon, nitrogen, oxygen, bromine, or iodine atom, respectively. 11 C.13 N, 15 O. 76 Br, or 124 The same applies to the introduction of I (see, e.g., Pimlott and Sutherland, Chem Soc Rev 2011, 40, 149; van der Born et al, Chem Soc Rev 2017, 46, 4709).

[0128] Thus, the term "PET tracer of the present invention" refers to a compound having a structure according to any of formulas I, Ia, Ib, Ic, II, IIa, IIb, IIc, III, IIIa, IIIb, and IIIc, as described in this patent application and further defined herein, or a compound having at least one radioisotope incorporated therein suitable for PET imaging, as individually disclosed herein. 11 C. 13 N, 15 O. 18 F, 76 Br, or 124 Preferred PET nucleotides for use in the compounds of the invention include, but are not limited to, 11 C. 13 N, 15 O. 18 F., especially 18 It's F.

[0129] The present invention includes within its scope the prodrugs of the compounds of the present invention.In general, such prodrugs are functional derivatives of the compounds described herein that can be easily converted in vivo, for example by endogenous enzymes in the intestine or blood, into the required GPR17-modulating compounds described herein.Conventional procedures for selecting and preparing suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed.H.Bundgaard, Elsevier, 1985.

[0130] Depending on their substitution pattern, the compounds of the present invention may or may not possess one or more optical stereocenters and may or may not exist as different enantiomers or diastereomers, and such enantiomers, diastereomers or other optical isomers are included within the scope of the present invention.

[0131] The compounds of the present invention may also exist in different crystalline forms, or polymorphs, all of which are included in the present invention.

[0132] The compounds of the invention can be included in pharmaceutical compositions that can also include a pharma- ceutically acceptable carrier. A "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient, or carrier, or other ingredient with which a compound of the invention is administered that one of ordinary skill in the art would understand to be pharma- ceutically acceptable.

[0133] The compounds of the present invention are useful in the prevention and / or treatment of certain diseases or disorders in animals, particularly humans, as described herein.

[0134] "Preventing" or "prevention" refers to a reduction in the risk of acquiring a disease or disorder (i.e., not developing at least one clinical symptom of the disease in a subject, particularly a human subject, who may have been exposed to or susceptible to the disease but has not yet experienced or displayed symptoms of the disease).

[0135] "Treating" or "treatment" of any disease or disorder, in one embodiment, includes ameliorating the disease or disorder (i.e., arresting or reducing the onset of the disease or reducing at least one of the clinical symptoms of the disease). In another embodiment, "treating" or "treatment" refers to improving at least one physical parameter, which may or may not be discernible by a subject, particularly a human subject, that is based on or associated with the disease or disorder being treated. In yet another embodiment, "treating" or "treatment" refers to modulating or alleviating the disease or disorder, either physically (e.g., discernible stabilization with no discernible symptoms), physiologically (e.g., stabilization of physiological parameters), or both. In yet another embodiment, "treating" or "treatment" refers to slowing the onset or progression of the disease or disorder. Thus, "treating" or "treatment" includes causal treatment of the underlying disease or disorder (i.e., disease modification), as well as treatment of signs and symptoms of the disease or disorder (with or without disease modification), as well as alleviating or ameliorating the disease or disorder, or its signs and symptoms.

[0136] "Diagnosis", "diagnosing" or "diagnosing" of a disease or disorder includes, in one embodiment, the identification and measurement of signs and symptoms associated with said disease. "Diagnosis", "diagnosing" or "diagnosing" includes, but is not limited to, the detection and / or measurement of reduced, increased, or otherwise misexpressed, activated, or distributed (with respect to time or location) GPR17 receptors as indicative of a GPR17-related disease or disorder, as compared to healthy subjects. In one example, GPR17 ligands can be used in the form of PET or SPECT tracers for such diagnosis, including the diagnosis of myelination disorders.

[0137] The terms "disease" and "disorder" are used largely interchangeably herein.

[0138] "Monitoring" refers to the observation of a disease, condition, or at least one medical parameter over a particular period of time. "Monitoring" also includes observing the effectiveness of a therapeutic agent with the assistance of a "companion drug."

[0139] As used herein, a "companion diagnostic" refers to a compound that can be used in combination with a therapeutic agent to determine the applicability (e.g., in terms of safety and efficacy) of said therapeutic agent to a particular patient. The use of a "companion diagnostic" can include diagnostic and monitoring steps.

[0140] The terms "animal" and "subject" include humans. The terms "human," "patient," and "human subject" are generally used interchangeably herein, unless expressly indicated.

[0141] The present invention also relates to a method of treating an animal disease or disorder, particularly a human disease or disorder, comprising administering a compound of the present invention in a therapeutically effective amount, as described in more detail herein. A "therapeutically effective amount" refers to the amount of a compound that, when administered to a subject, particularly a human subject, to treat a disease, is sufficient to effect such treatment of the disease. A "therapeutically effective amount" may vary depending on the compound, the disease and its severity, and the condition, age, weight, sex, etc., of the subject, particularly a human subject, to be treated.

[0142] As used herein, the term "multiple sclerosis" refers to a disease classified under section G35 of the 2018 US edition of the ICD-10-CM diagnostic codes.

[0143] The term "GPR17 modulator" as used herein is meant to describe a compound that can regulate the activity of GPR17 receptor, in particular a compound that can reduce GPR17 activity. Such "negative GPR17 modulators" include GPR17 antagonists that can block the effect of GPR17 agonists, as well as GPR17 inverse agonists that can inhibit constitutively active GPR17 receptors or receptor mutants. The preferred GPR17 modulators of the present invention are inverse GPR17 agonists.

[0144] "Halogen" includes fluorine, chlorine, bromine and iodine atoms. "Cyano" refers to the group --CN. "Azide" refers to the group -N=N=N. "Oxo" refers to the group -C(=O)OH "Oxo" refers to the group -C(=O)-

[0145] Whenever numbers appear in subscript following the letter "C", these numbers (whether in parentheses or not) indicate the range of carbon atoms in the respective group immediately following the number. For example, "C 1‐3 " and "(C 1‐3 )" both refer to groups containing 1 to 3 C atoms, as further specified herein.

[0146] "Alkyl" includes saturated aliphatic hydrocarbyl groups. The hydrocarbon chain can be either straight or branched. Examples of "alkyl" include alkyl groups having 1 to 5 carbon atoms ("C 1‐5 alkyl"), 1 to 4 carbon atoms ("C 1‐4 alkyl"), 1 to 3 carbon atoms ("C 1‐3 alkyl) or 1 to 2 carbon atoms ("C 1‐2This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, t-amyl, etc. Any number of C atoms in an alkyl or other group may be indicated herein with or without parentheses.

[0147] As used interchangeably herein, "alkyloxy" and "alkoxy" (together alkoxy(alkyloxy)) include the group -OR, where R is an "alkyl" as further defined and exemplified herein. Particular alkoxy(alkyloxy) groups include, by way of example, methoxy (methyloxy), ethoxy (ethyloxy), n-propoxy (n-propyloxy), isopropoxy (isopropyloxy), n-butoxy (n-butyloxy), tert-butoxy (tert-butyloxy), sec-butoxy (sec-butyloxy), isobutoxy (isobutyloxy), and the like.

[0148] The term "fluoroalkyl" as used herein refers to an "alkyl" as described herein that is substituted with one or more fluorine atoms. 1‐3 Representative examples of alkyl groups include, but are not limited to, -CF3, -CHF2, -CHFCHF2, and -CH2CF3. A particularly preferred fluoroalkyl group is difluoromethyl-CHF2.

[0149] The terms "fluoroalkyloxy" or "fluoroalkoxy" as used interchangeably herein refer to "alkoxy(alkyloxy)" as described herein substituted with one or more fluorine atoms.

[0150] Fluoro(C 1‐3 )Alkoxy group (fluoro(C 1‐3 Representative examples of alkyloxy groups include, but are not limited to, -OCF3, -OCHF2, -OCHFCH2F, and -OCH2CF3.

[0151] The term "fluoromethoxy" as used herein refers to a methoxy group substituted with one to three fluorine atoms. The term "monofluoromethoxy" refers to a methoxy group substituted with one fluoro atom. The term "difluoromethoxy" as used herein refers to a methoxy group substituted with two fluorine atoms. The term "trifluoromethoxy" refers to a methoxy group substituted with three fluorine atoms.

[0152] The term "fluoroethoxy" as used herein refers to an ethoxy group substituted with one to three fluorine atoms. The term "monofluoroethoxy" as used herein refers to an ethoxy group substituted with one fluorine atom. A particularly preferred monofluoroethoxy is the -OCH2CH2F group. The term "difluoroethoxy" as used herein refers to an ethoxy group substituted with two fluorine atoms. A particularly preferred difluoroethoxy is the -OCH2CHF2 group. The term "trifluoroethoxy" refers to an ethoxy group substituted with three fluorine atoms. A preferred trifluoroethoxy group is the -OCH2CF3 group.

[0153] The term "fluoromethoxyethoxy" refers to a terminal fluoromethoxy group, further defined herein, attached to an ethoxy group. A preferred "fluoromethoxyethoxy" is difluoromethoxyethoxy, represented by -OCH2CH2OCHF2.

[0154] The term "hydroxyalkyl" as used herein refers to an "alkyl" as defined herein (e.g., a methyl, ethyl, or propyl group) that is substituted with one or more hydroxy groups. Hydroxy (C 1‐3 Representative examples of alkyl groups include, but are not limited to, -CH2CH2OH (monohydroxyethyl), -CH2CH2CH2OH (monohydroxypropyl), and -CH2CH(OH)CH2OH (dihydroxypropyl).

[0155] The term "hydroxyalkoxy" ("hydroxyalkyloxy") as used herein refers to an "alkoxy" ("alkyloxy") as described herein that is substituted with one or more hydroxy groups. 1‐3 Representative examples of alkyl groups include, but are not limited to, -OCH2CH2OH (monohydroxyethoxy) and -OCH2CH2CH2OH (monohydroxypropyloxy).

[0156] The term "fluorohydroxyalkyl" or "fluorohydroxyalkoxy" as used herein refers to the respective alkyl or alkoxy groups as defined herein, having the specified amount of C atoms substituted with at least one hydroxy group and at least one fluoro atom. Preferred examples are groups substituted with one hydroxy and one to three fluoro atoms, such as trifluoromonohydroxypropyl (e.g., CH2CH(OH)CF3) and monofluoromonohydroxypropyl (e.g., -CH2CHFCH2OH or -CH2CH(OH)CH2F).

[0157] The term "cycloalkyl" as used herein refers to a monovalent group derived from a saturated hydrocarbon, which can be unsubstituted or substituted with one or more substituents as further indicated herein. A "cycloalkyl" refers to a group having at least three, and preferably at least five, ring-forming carbon atoms ("C 3‐5 cycloalkyl"), or four ring-forming atoms ("C 3‐4 Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, and cyclopentyl.

[0158] As used herein, the term "heterocycloalkyl" refers to a saturated ring containing at least two ring-forming carbon atoms and at least one ring-forming heteroatom, preferably selected from oxygen, sulfur and nitrogen, each of which can be unsubstituted or further substituted with one or more substituents described herein. 3‐5The term "heterocycloalkyl" refers to a heterocycloalkyl containing 3 to 5 ring-forming atoms. Suitable heterocycloalkyl groups include epoxide, oxetanyl, azetidinyl, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, isothiazolidinyl and imidazolidinyl. Preferred heterocycloalkyls are those containing one oxygen atom, such as oxetanyl or tetrahydrofuranyl. EXAMPLES

[0159] Experimental Section Test Part: A. chemistry The compounds of the invention and routes for their synthesis are described in more detail below.

[0160] A general method for preparing AI compounds. The compounds of formula I according to the invention can be prepared analogously to conventional methods understood by those skilled in the art of synthetic organic chemistry.

[0161] References herein to the synthesis of compounds of general formula I equally apply to applicable compounds of subformulae II, III, and to the specific exemplary compounds disclosed herein.

[0162] According to one embodiment, some compounds of general formula I can be prepared by reaction of a sulfonyl chloride of formula XII with an aniline of formula X according to the following scheme: [ka]

[0163] The reaction can be carried out in the presence of a base such as pyridine used as a solvent at room temperature or with heating, preferably at a temperature in the range of 50 to 100° C. The use of a catalytic amount of a base such as DMAP can also be beneficial.

[0164] Compounds of formula XII can be prepared by sulfonyl chlorination of compounds of formula XI according to the following scheme: [ka]

[0165] The reaction can be carried out in the presence of a sulfonyl chlorinating agent, such as chlorosulfonic acid, in a polar solvent, such as acetonitrile, at room temperature.

[0166] Alternatively, the reaction can be carried out in the presence of a sulfonylating agent such as sulfur trioxide / DMF complex in a solvent such as dichloromethane at room temperature. The unisolated sulfonic acid intermediate could be reacted successively with a chlorinating agent such as thionyl chloride at room temperature.

[0167] Compounds of formula XI can be prepared by alkylation of compounds of formula IX by nucleophilic substitution with alkylating agents such as iodine or trifluoromethanesulfonate derivatives in the presence of a base such as sodium hydride in a solvent such as DMF at low or room temperature. [ka]

[0168] Alternatively, the reaction can be carried out by Michael addition of compound IX onto an activated vinyl such as an acrylate in the presence of a base such as sodium hydride in a solvent such as DMF at room temperature.

[0169] According to one embodiment, some compounds of general formula I can be prepared by alkylation of a compound of formula XIII-P1, where P1 is a protecting group such as methoxymethyl, according to the following scheme: [ka]

[0170] This reaction can be carried out in the presence of a base such as potassium hydroxide in a polar solvent such as DMSO, followed by addition of an alkylating agent such as an iodo derivative with heating at a temperature ranging from 50 to 120° C. Subsequent deprotection can be carried out under acidic conditions such as concentrated hydrochloric acid in a solvent such as methanol.

[0171] Compounds of formula XIII-P1, where P1 is a protecting group such as methoxymethyl, can be prepared by a protection and deprotection sequence of compounds of formula XIII-P2, where P2 is a protecting group such as phenylsulfonyl (PhSO2), according to the following scheme: [ka]

[0172] This reaction can be carried out by reaction of compound XIII-P2, where P2 is a protecting group such as phenylsulfonyl, with chloromethyl ether or a similar reagent in the presence of a base such as DIPEA in a solvent such as DCM at room temperature. Subsequent deprotection of the P2 group can be carried out in the presence of tetrabutylammonium fluoride in a solvent such as THF, preferably with heating at a temperature ranging from 60 to 90° C.

[0173] Compounds of formula XIII-P2, where P2 is a protecting group such as phenylsulfonyl, can be prepared by reaction of a sulfonyl chloride of formula XII-P2 with an aniline of formula X. The reaction can be carried out at room temperature in the presence of a base such as pyridine used as a solvent. [ka]

[0174] Compounds of formula XII-P2, where P2 is a protecting group such as phenylsulfonyl, can be prepared by chlorosulfonylation of compounds of formula XI-P2 according to the following scheme: [ka]

[0175] The reaction can be carried out in the presence of chlorosulfonic acid in a polar solvent such as acetonitrile at room temperature.

[0176] Compounds of formula XI-P2, where P2 is a protecting group such as phenylsulfonyl, can be prepared by protecting compounds of formula IX according to the following scheme: [ka]

[0177] This reaction can be carried out by reacting compound IX with benzenesulfonyl chloride or a similar reagent in the presence of a base such as sodium hydroxide or sodium iodide in a solvent such as DCM or DMF, or according to any method known to one skilled in the art.

[0178] Anilines of formula X are commercially available or can be prepared according to any method known to one skilled in the art or using procedures described in the literature. Alternatively, some anilines of formula X can be prepared by reducing compound VIII according to the following scheme: [ka]

[0179] This reaction can be carried out in the presence of a catalytic amount of palladium on charcoal in a polar solvent such as ethyl acetate or methanol, using any reducing agent such as iron in the presence of an acid such as acetic acid or hydrogen, or according to any method known to one skilled in the art.

[0180] Compounds of formula VIII are commercially available or can be prepared according to literature procedures or any other method known to one skilled in the art.

[0181] Compounds of formula IX are either commercially available or can be prepared by suitable methods known to those skilled in the art.

[0182] A-II. Abbreviations / Frequently Occurring Reagents Ac: Acetyl ACN: Acetonitrile AcOH: acetic acid Brine: Saturated aqueous sodium chloride solution Boc: tert-butoxycarbonyl nBu: n-butyl tBu: tert-butyl conc.:concentration Cy: Cyclohexyl d:day DCM: dichloromethane DIPEA: Diisopropylethylamine DMAP: 4-Dimethylaminopyridine DMF: N,N-dimethylformamide DMSO: Dimethyl sulfoxide ES + : Electrospray positive ionization ES-: Electrospray negative ionization ESI: electrospray ionization EtOAc: ethyl acetate h: time LCMS: Liquid Chromatography Mass Spectrometry Me: Methyl MeOH: Methanol min:minutes mw: microwave NMR: nuclear magnetic resonance rt: room temperature TBAHSA: Tetrabutylammonium hydrogen sulfate TBAF: Tetrabutylammonium fluoride TFAA: Trifluoroacetic anhydride THF: tetrahydrofuran TLC: Thin Layer Chromatography

[0183] A-III. Analysis method Commercially available solvents and reagents were generally used without further purification, including anhydrous solvents where necessary (usually Sure-Seal™ products from Aldrich Chemical Company or AcroSeal™ from ACROS Organics). Reactions were generally followed by thin layer chromatography or liquid chromatography mass spectrometry.

[0184] Mass spectrometry measurements in LCMS mode are performed using different methods and instruments:

[0185] - Basic LCMS method 1: Mass spectrometry (MS) spectra were recorded on a LCMS-2010EV mass spectrometer (Shimadzu) with electrospray ionization (ESI) connected to a HPLC Modular Prominence (Shimadzu) using an Xbridge C18-2.1x30mm, 2.5μm (Waters) column. A volume of 3μL of sample solution with a concentration of approximately 1mg / mL was injected. The mobile phase for the basic conditions was a mixture of A) 5mM ammonium formate + 0.1% aqueous ammonia B) 5% mobile phase A + 0.1% ammonia in acetonitrile. The gradient used was as follows: 5:95 (B / A) to 95:5 (B / A) in 4 min, then hold at 95:5 (B / A) for the next 1 min.

[0186] -Neutral LCMS Method 2: Mass spectrometry (MS) spectra were recorded on an LCMS instrument (Applied Biosystems API 2000 LC / MS / MS, HPLC Agilent 1100) using the following procedure: 1.0 mg mL in ACN (solvent A) or water (containing 2 mM ammonium acetate):MeOH 90:10 (solvent B). ‐1Compounds were dissolved at a concentration of 0.01% and sonicated if necessary until completely dissolved. 10 μL of the solution was then injected onto a Phenomenex Luna C18 HPLC column (50 × 2.00 mm, 3 μm particle size) and eluted with a gradient of water:ACN (gradient A) or water:MeOH (gradient B) from 90:10 to 0:100 within 10 min. The gradient was started after 1 min, followed by 300 μL min of pure organic solvent. ‐1 The elution was performed for 10 min at a flow rate of 100 rpm. UV absorption was detected at 220–400 nm using a diode array detector (DAD).

[0187] The crude material could be purified by normal phase chromatography or recrystallization.

[0188] Normal phase chromatography was performed using a silica gel column (100:200 mesh silica gel or cartridges for flash chromatography systems such as the Isolera™ Four from Biotage® or Teledyne Isco CombiFlash®).

[0189] NMR spectra were recorded on a variety of instruments. - Varian 400 MHz NMR spectrometer. Acquisition time (at) = 2.0 s, relaxation delay (d1) = 2.0 s, line broadening (lb) = 0.5 Hz. -Bruker Avance III 600 MHz NMR spectrometer

[0190] Chemical shifts are referenced to signals due to residual protons of the deuterated solvent (DMSO-d6 or CDCl3). Chemical shifts are in parts per million (ppm) and coupling constants (J) are expressed in Hertz (Hz). Spin multiplicities are expressed as broad (br), singlet (s), doublet (d), triplet (t), quartet (q), or multiplet (m).

[0191] The products were typically dried under vacuum prior to submission for final analysis and biological testing.

[0192] A-IV: Compounds and synthetic examples The names of the following compounds are IUPAC names generated by Biovia Draw version 16.1 for intermediates of formulas X, XI, XII and by PipelinePilot2018 using OpenEyeoemetachem version 1.4.5 for example compounds of formula I.

[0193] Intermediates If commercially available, starting materials are identified by CAS Registry Numbers.

[0194] A. Synthesis of intermediates of formula X A.1. Synthesis of 6-chloro-5-fluoro-2-methoxy-pyridin-3-amine X-1: [ka]

[0195] Step-1: Synthesis of 2,5-difluoro-1-oxide-pyridin-1-ium X-1a: To a solution of 2,5-difluoropyridine (3.00 g, 26.1 mmol) in DCM (120 mL) was added urea hydrogen peroxide (7.36 g, 78.2 mmol) and the reaction mixture was stirred at room temperature for 10 min. The reaction mixture was cooled at 0 °C followed by dropwise addition of trifluoroacetic anhydride (12 mL). The reaction mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was diluted with aqueous NaHCO3 (120 mL) and extracted with DCM (3 x 80 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum to give 2,5-difluoro-1-oxide-pyridin-1-ium X-1a (1.00 g) as an off-white solid.

[0196] This compound was used as is for the next reaction without further purification. Yield: 29%. 1H NMR (400 MHz, DMSO-d6) δ 7.39-7.47 (m, 1H), 7.50 (m, 1H), 8.48-8.57 (m, 1H).

[0197] Step-2: Synthesis of 2-chloro-3,6-difluoro-pyridine X-1b: To a solution of 2,5-difluoro-1-oxide-pyridin-1-ium X-1a (0.95 g, 7.25 mmol) in DCM (30 mL) was added POCl3 (1.33 mL, 14.5 mmol) dropwise at 0 °C. The reaction mixture was stirred at the same temperature for 5 min, followed by the addition of DMF (0.60 mL). The reaction mixture was stirred at room temperature for 6 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was quenched with saturated NaHCO3 (50 mL) solution and extracted with EtOAc (2 x 50 mL). The organic layer was separated, dried over anhydrous Na2SO4, and concentrated under vacuum to give 2-chloro-3,6-difluoro-pyridine X-1b (0.65 g) as a light brown liquid. This compound was used as such for the next reaction without further purification.

[0198] Yield: 60%. 1 H NMR (400 MHz, DMSO-d6) δ 7.35-7.39 (m, 1H), 8.15-8.23 (m, 1H).

[0199] Step-3: Synthesis of 2-chloro-3,6-difluoro-5-nitro-pyridine X-1c: To a solution of 2-chloro-3,6-difluoro-pyridine X-1b (0.60 g, 4.01 mmol) in fuming HNO3 (4.19 mL, 100 mmol) was added concentrated H2SO4 (3.21 mL, 60.2 mmol) dropwise, maintaining the temperature below 40 °C. The reaction mixture was then heated at 60 °C for 30 min. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was cooled, poured onto crushed ice and extracted with DCM (2 × 50 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The resulting crude product was purified by column chromatography (silica, 100-200 mesh, 10% EtOAc in hexane) to give 2-chloro-3,6-difluoro-5-nitro-pyridine X-1c (0.185 g) as a pale yellow liquid.

[0200] Yield: 24%. 1 H NMR (400 MHz, DMSO-d6) δ 9.10-9.14 (m, 1H).

[0201] Step-4: Synthesis of 2-chloro-3-fluoro-6-methoxy-5-nitro-pyridine X-1d: To a solution of 2-chloro-3,6-difluoro-5-nitro-pyridine X-1c (0.67 g, 3.44 mmol) in MeOH (10 mL), NaOMe (0.82 mL, 3.79 mmol) was added dropwise at -40 °C and the reaction mixture was stirred at the same temperature for 20 min. The reaction progress was monitored by TLC. After completion, the reaction mixture was poured into ice-cold 1N HCl (10 mL) and extracted with hexane (2x15 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum to give 2-chloro-3-fluoro-6-methoxy-5-nitro-pyridine X-1d (0.40 g) as a yellow solid.

[0202] This compound was used as is for the next reaction without further purification. Yield: 56%. 1H NMR (400 MHz, DMSO-d6) δ 4.03 (s, 3H), 8.82 (d, J=7.83 Hz, 1H).

[0203] Step-5: Synthesis of 6-chloro-5-fluoro-2-methoxy-pyridin-3-amine X-1: To a stirred solution of 2-chloro-3-fluoro-6-methoxy-5-nitro-pyridine X-1d (0.20 g, 0.97 mmol) in acetic acid (4 mL) was added iron (0.22 g, 3.87 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was poured into ice-cold saturated NaHCO3 (25 mL). The reaction mixture was filtered through a pad of Celite, washed with EtOAc (2 x 15 mL) and the aqueous layer was extracted with EtOAc (2 x 15 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The resulting crude product was purified by column chromatography (silica, 100-200 mesh, 4% EtOAc in hexane) to give 6-chloro-5-fluoro-2-methoxy-pyridine-3-amine X-1 (0.11 g, 63%) as an off-white solid.

[0204] Yield: 63%. Basic LCMS method 1 (ES + ):177(M+H) + , 98% purity 1 H NMR (400 MHz, DMSO-d6) δ 3.84 (s, 3H), 5.49 (brs, 2H), 6.90 (d, J=9.78 Hz, 1H).

[0205] A.2. Synthesis of 6-(difluoromethoxy)-5-fluoro-2-methoxy-pyridin-3-amine X-2: [ka]

[0206] Step-1: Synthesis of 3-fluoro-6-methoxy-5-nitro-pyridin-2-ol X-2a: To a solution of 2-chloro-3-fluoro-6-methoxy-5-nitro-pyridine X-1d (0.90 g, 4.36 mmol) in H2O (6 mL) was added KOH (0.61 g, 10.9 mmol) and the mixture was heated at 80 °C for 16 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (3 x 80 mL). The organic layer was separated, dried over anhydrous Na2SO4, and concentrated under vacuum to give 3-fluoro-6-methoxy-5-nitro-pyridine-2-ol X-2a (crude 0.30 g) as a pale yellow solid.

[0207] This compound was used as is for the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 3.99 (s, 3H), 8.42 (d, J=9.60 Hz, 1H), 12.12 (s, 1H).

[0208] Step-2: Synthesis of 2-(difluoromethoxy)-3-fluoro-6-methoxy-5-nitro-pyridine X-2b: To a solution of 3-fluoro-6-methoxy-5-nitro-pyridin-2-ol X-2a (0.29 g, 1.54 mmol) in CH3CN (4 mL) was added a solution of KOH (0.87 g, 15.4 mmol) in H2O (1 mL) and bromodifluoromethyl diethylphosphonate (2.74 mL, 15.4 mmol) at 40 °C. The reaction mixture was stirred at the same temperature for 4 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (3 x 40 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum. The obtained crude product was purified by flash chromatography (2-5% EtOAc in hexane) to give 2-(difluoromethoxy)-3-fluoro-6-methoxy-5-nitro-pyridine X-2b (0.24 g) as a pale yellow liquid.

[0209] This compound was used as is for the next reaction without further purification. Yield: 65%. 1 H NMR (400 MHz, DMSO-d6) δ 4.04 (s, 3H), 7.90 (t, J=70.8 Hz, 1H), 8.80 (d, J=9.60 Hz, 1H).

[0210] Step-3: Synthesis of 6-(difluoromethoxy)-5-fluoro-2-methoxy-pyridin-3-amine X-2: To a solution of 2-(difluoromethoxy)-3-fluoro-6-methoxy-5-nitro-pyridine X-2b (0.23 g, 0.97 mmol) in CH3COOH (8 mL) was added Fe (0.27 g, 4.83 mmol) slowly at 0 °C. The reaction mixture was stirred at room temperature for 4 h. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was filtered through a pad of Celite, washed with EtOAc (80 mL) and the filtrate was concentrated under vacuum. The residue was poured into saturated aqueous NaHCO3 (80 mL) and extracted with EtOAc (2 x 70 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum to give 6-(difluoromethoxy)-5-fluoro-2-methoxy-pyridine-3-amine X-2 (0.18 g) as a brown liquid.

[0211] This compound was used as is for the next reaction without further purification. Yield: 77%. Basic LCMS Method 1 (ES - ):207(M-H) - , 85% purity. 1 H NMR (400 MHz, DMSO-d6) δ 3.84 (s, 3H), 5.18 (brs, 2H), 6.95 (d, J=10.8 Hz, 1H), 7.39 (t, J=74 Hz, 1H).

[0212] A.3. Synthesis of 5-chloro-3-fluoro-6-methoxy-pyridin-2-amine X-3: [ka]

[0213] Step-1: Synthesis of 5-chloro-3,6-difluoro-pyridin-2-amine X-3a: To a solution of 3-chloro-2,5,6-trifluoro-pyridine (0.50 g, 2.98 mmol) in dioxane (10 mL) was added 25% aqueous NH3 (4 mL) and the reaction mixture was heated in a steel bath at 100 °C for 12 h. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (400 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated under vacuum to give 5-chloro-3,6-difluoro-pyridin-2-amine X-3a (crude 0.41 g) as a yellow solid.

[0214] This compound was used as is for the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 6.85 (s, 2H), 7.80-7.85 (m, 1H).

[0215] Step-2: Synthesis of 5-chloro-3-fluoro-6-methoxy-pyridin-2-amine X-3: To a solution of 5-chloro-3,6-difluoro-pyridin-2-amine X-14 (0.50 g, 2.97 mmol) in MeOH (25 mL) was added NaOMe (0.48 g, 8.92 mmol) and the reaction mixture was heated at 100° C. for 24 h. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was concentrated under vacuum. The residue was diluted with H2O (100 mL) and extracted with DCM (200 mL). The organic layer was separated, dried over anhydrous Na2SO4, and concentrated under vacuum to give 5-chloro-3-fluoro-6-methoxy-pyridin-2-amine X-3 (0.40 g) as an off-white solid.

[0216] This compound was used as is for the next reaction without further purification. Yield: 72% 1 H NMR (400 MHz, DMSO-d6) δ 3.80 (s, 3H) 6.35 (s, 2H) 7.58 (d, J=9.78 Hz, 1H).

[0217] B. Synthesis of intermediates of formula XI B.1. Synthesis of 6-chloro-1-methyl-1H-indole XI-1: [ka]

[0218] To a solution of 6-chloroindole (0.80 g, 5.29 mmol) in DMF (15 mL) was added NaH (0.25 g, 10.5 mmol) at 0 °C and the reaction mixture was stirred at the same temperature for 30 min. Methyl iodide (2.40 mL, 6.34 mmol) was added at 0 °C and the reaction mixture was stirred at the same temperature for 2 h. The reaction progress was monitored by TLC and LCMS. After completion, the reaction mixture was quenched with ice-cold H2O (15 mL) and extracted with EtOAc (2 x 30 mL). The organic layer was separated, washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated in vacuum. The obtained crude product was purified by column chromatography (silica, 100-200 mesh, 30% EtOAc in hexane) to give 6-chloro-1-methyl-1H-indole XI-1 (0.60 g) as a white solid.

[0219] Yield: 68%. 1 H NMR (400 MHz, CDCl3) δ 3.78 (s, 3H) 6.48 (d, J=2.93 Hz, 1H) 7.06 (d, J=3.42 Hz, 1H) 7.09 (d, J=8.56 Hz, 1H) 7.34 (s, 1H) 7.54 (d, J=8.31 Hz, 1H).

[0220] B.2. Synthesis of 6-chloro-1-(2,2-difluoroethyl)pyrrolo[2,3-b]pyridine XI-2: [ka]

[0221] A solution of 6-chloro-7-azaindole (300 mg, 1.97 mmol) in 10 mL of DMF was treated with sodium hydride (66% in paraffin, 500 mg, 13.8 mmol) and stirred at room temperature for 1 h. Subsequently, 2,2-difluoroethyl trifluoromethanesulfonate (0.4 mL, 3.0 mmol) was added at room temperature. After stirring for 16 h, water (100 mL) was added and the resulting precipitate was filtered under reduced pressure, washed with water and dried at 50 °C. The crude product was subsequently purified by column chromatography on silica gel 60 (eluent: pure dichloromethane) to give 6-chloro-1-(2,2-difluoroethyl)pyrrolo[2,3-b]pyridine XI-2 as colorless crystals.

[0222] Yield: 91%. 1 H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 3.6 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H), 6.07 (tt, 2JH,F = 55.5, J = 4.2 Hz, 1H), 4.59 (td, 3JH,F = 14.0, J = 4.3 Hz, 2H).

[0223] B.3. Synthesis of methyl 3-(6-chloro-1H-indol-1-yl)-2-fluoropropanoate XI-3: [ka]

[0224] To a solution of 6-chloroindole (1.06 g, 6.99 mmol) and Cs2CO3 (2.73 g, 8.39 mmol) in DMF (10 mL) was added dropwise methyl 2-fluoroacrylate (0.8 g, 7.69 mmol). Then the mixture was stirred at room temperature overnight. The reaction was quenched with H2O (50 mL) and extracted with Et2O (50 mL). The organic phase was washed with brine and dried over MgSO4. After removing the solvent under reduced pressure, the residue was purified by column chromatography on silica gel to give methyl 3-(6-chloro-1H-indol-1-yl)-2-fluoropropanoate XI-3 (910 mg).

[0225] Yield: 51%. 1 H NMR (600 MHz, CDCl3) δ 7.52 (d, J = 8.4 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.12 - 7.07 (m, 2H), 6.51 (dd, J = 3.2, 0.9 Hz, 1H), 5.20 (ddd, J = 48.3, 6.3, 3.0 Hz, 1H), 4.66 - 4.47 (m, 2H), 3.76 (s, 3H).

[0226] B.4. Synthesis of methyl 3-(6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XI-4: [ka]

[0227] To a solution of 6-chloro-1H-pyrrolo[2,3-b]pyridine (1.07 g, 6.99 mmol) and Cs2CO3 (2.73 g, 8.39 mmol) in DMF (10 mL) was added dropwise methyl 2-fluoroacrylate (0.8 g, 7.69 mmol). The mixture was stirred at room temperature overnight, quenched with H2O (50 mL), and extracted with Et2O (50 mL). The organic phase was washed with brine, dried over MgSO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel to give methyl 3-(6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XI-4 (1.36 g).

[0228] Yield: 76%. 1 H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 8.1 Hz, 1H), 7.24 (dd, J = 3.6, 1.4 Hz, 1H), 7.09 (d, J = 8.1 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H), 5.28 (ddd, J = 48.4, 6.6, 3.4 Hz, 1H), 4.91 - 4.54 (m, 2H), 3.78 (s, 3H).

[0229] C. Synthesis of intermediates of formula XII C.1. Synthesis of 6-chloro-1-methyl-1H-indole-3-sulfonyl chloride XII-1: [ka]

[0230] To a solution of 6-chloro-1-methyl-1H-indole XI-1 (0.50 g, 2.85 mmol) in CH3CN (5 mL) was added ClSO3H (1 mL) dropwise at 0 °C and the reaction mixture was stirred at room temperature for 2 h. The reaction progress was monitored by TLC and LCMS. After completion, the reaction mixture was poured into crushed ice H2O (60 mL) and extracted with EtOAc (2 × 40 mL). The organic layer was separated, dried over anhydrous Na2SO4 and concentrated in vacuo to give 6-chloro-1-methyl-1H-indole-3-sulfonyl chloride XII-1 (0.705 g) as a brown solid.

[0231] This compound was used as is for the next reaction without further purification. Yield: 78% Basic LCMS Method 1 (ES - ):244(M-H) - The corresponding sulfonic acid, purity 83%. 1 H NMR (400 MHz, DMSO-d6) δ 7.72 (d, J=8.80 Hz, 1H) 7.52 (d, J=1.96 Hz, 1H) 7.43 (m, 1H) 7.05-7.09 (m, 1H) 3.73 (s, 3H)

[0232] C.2. Synthesis of 6-chloro-1-methyl-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-2: [ka]

[0233] A solution of 6-chloro-7-azaindole (300 mg, 1.97 mmol) in 10 mL of DMF was treated with sodium hydride (66% in paraffin, 500 mg, 13.8 mmol) and stirred at room temperature for 1 h. Subsequently, methyl iodide (0.2 mL, 3.2 mmol) was added at room temperature. After stirring for 16 h, water (100 mL) was added and the suspension was extracted with ethyl acetate (3x30 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The obtained material was characterized only by TLC and used directly in the next step. The crude material (ca. 1.9 mmol) was dissolved in dichloromethane (15 mL) and treated with sulfur trioxide / DMF complex (500 mg, 3.27 mmol). The mixture was stirred at room temperature for 0.5 h. Subsequently, thionyl chloride (0.6 mL, 8.34 mmol) was added and the formed suspension was stirred at room temperature for 14 days. The resulting clear solution was controlled by TLC. The mixture was hydrolyzed with a saturated aqueous solution of NaHCO3 (75 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was crystallized from dichloromethane / petroleum ether to give 320 mg of 6-chloro-1-methyl-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-2 as colorless crystals.

[0234] Yield: 61% 1 H NMR (600 MHz, CDCl3) δ 8.24 (d, J = 8.4 Hz, 1H), 7.96 (s, 1H), 7.37 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H).

[0235] C.3. Synthesis of 6-chloro-1-(2,2-difluoroethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-3: [ka]

[0236] A solution of 6-chloro-1-(2,2-difluoroethyl)pyrrolo[2,3-b]pyridine XI-2 (367 mg, 1.7 mmol) in dichloromethane was treated with sulfur trioxide / DMF complex (500 mg, 3.27 mmol). The mixture was stirred at room temperature for 0.5 h (TLC control showed no further starting material and complete conversion to the expected sulfonic acid, eluent: pure dichloromethane). Subsequently, thionyl chloride (0.6 mL, 8.34 mmol) was added and the mixture was stirred at room temperature for 16 h. The reaction was controlled by TLC (one spot of the expected product was observed, eluent: pure dichloromethane). The mixture was hydrolyzed with a saturated aqueous solution of NaHCO3 (75 mL) and extracted with dichloromethane (3 x 30 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was crystallized from petroleum ether to give 325 mg of 6-chloro-1-(2,2-difluoroethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-3 as colorless crystals.

[0237] Yield: 67% 1 H NMR (600 MHz, CDCl3) δ 8.29 (d, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.42 (d, J = 8.3 Hz, 1H), 6.17 (tt, J = 54.9 Hz, J = 3.9 Hz, 1H), 4.71 (td, J = 14.0 Hz, J = 3.9 Hz, 2H).

[0238] C.4. Synthesis of methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-indol-1-yl)-2-fluoropropanoate XII-4: [ka]

[0239] To a solution of methyl 3-(6-chloro-1H-indol-1-yl)-2-fluoropropanoate XI-3 (330 mg, 1.29 mmol) in CHCl (10 mL) was added SO·DMF (593 mg, 3.87 mmol). After stirring at room temperature for 48 h, SOCl (0.56 mL, 7.7 mmol) was added and the mixture was stirred for another 24 h. The mixture was subsequently quenched with H0 (20 mL) and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over MgSO and concentrated under reduced pressure to give methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-indol-1-yl)-2-fluoropropanoate XII-4 (288 mg), which was used directly in the next step without further purification or characterization. Yield: 63%

[0240] C.5. Synthesis of methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XII-5: [ka]

[0241] To a solution of methyl 3-(6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XI-4 (300 mg, 1.17 mmol) in CHCl (10 mL) was added SO·DMF (537 mg, 3.51 mmol). After stirring at room temperature for 48 h, SOCl (0.5 mL, 7.02 mmol) was added and the mixture was stirred for another 24 h. The mixture was subsequently quenched with H0 (20 mL) and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over MgSO, filtered and concentrated under reduced pressure to give methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XII-5 (215 mg), which was used directly in the next step without further purification or characterization. Yield: 52%

[0242] C.6. Synthesis of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 [ka]

[0243] Step-1: Synthesis of 1-(benzenesulfonyl)-6-chloro-indole XII-6a A suspension of finely powdered sodium hydroxide (24.5 g, 613 mmol) in dichloromethane (300 mL) was stirred in an ice bath and 6-chloroindole (30 g, 197 mmol) was added in one portion followed by tetrabutylammonium hydrogen sulfate (1.75 g, 5.15 mmol). Benzenesulfonyl chloride (2.2 mL, 218 mmol) was then added dropwise over 20 min and the reaction mixture was stirred at 0 °C for 1 h. The ice bath was then removed and the mixture was stirred at room temperature for an additional 1 h. When LCMS showed the reaction was complete, the reaction mixture was filtered through a pad of Celite, the latter was washed with DCM and the combined filtrate and washings were evaporated to dryness. The product was triturated with ether, filtered, washed with a small amount of ether then hexane, dried and the filtrate was concentrated to give a second crop containing a total of 50.54 g of 1-(benzenesulfonyl)-6-chloro-indole XII-6a as a light brown solid.

[0244] Yield: 88%. 1 H NMR (400 MHz, CDCl3) δ 8.04 (dd, J= 1.8, 0.9 Hz, 1H), 7.91 (t, J = 1.4 Hz, 1H), 7.89 (t, J = 1.8 Hz, 1H), 7.67-7.54 (m, 2H), 7.53-7.48 (m, 2H), 7.48-7.42 (m, 1H), 7.23 (dd, J = 8.4, 1.9 Hz, 1H), 6.65 (dd, J = 3.7, 0.9 Hz, 1H).

[0245] Step-2: Synthesis of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 A solution of 1-(benzenesulfonyl)-6-chloro-indole XII-6a (50 g, 171.4 mmol) in acetonitrile (500 mL) was stirred in an ice bath, chlorosulfonic acid (100.8 g, 856.8 mmol) was added dropwise over 20 min, and the reaction mixture was stirred at room temperature for 5 days. It was then slowly poured into ice water (2.2 L) with stirring for 20 min, filtered, washed several times with water, and sucked dry to give 63.77 g of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 as a light brown solid.

[0246] Yield: 95%. 1 H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 8.07 (d, J = 1.8 Hz, 1H), 8.04 (t, J= 1.3 Hz, 1H), 8.02 (d, J = 1.5 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.79-7.70 (m, 1H), 7.68-7.59 (m, 2H), 7.47 (dd, J = 8.6, 1.8 Hz, 1H).

[0247] C.7. Synthesis of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-7 [ka]

[0248] Step-1: Synthesis of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine XII-7a To a solution of 6-chloro-1H-pyrrolo[2,3-b]pyridine (1.37 g, 8.97 mmol) in DMF (100 mL) was added sodium hydride (60% in paraffin, 1 g, 41 mmol). The solution was stirred for 30 min and warmed from 0 °C to room temperature. Subsequently, benzenesulfonic acid chloride (1.5 mL, 11.8 mmol) was added dropwise. The suspension was stirred at room temperature for 3 h and hydrolyzed with ice water. The solid obtained was filtered off under reduced pressure, washed thoroughly with water (75 mL) and finally with petroleum ether (15 mL). The material obtained was dried at 60 °C and purified by column chromatography (eluent: pure dichloromethane) to give 856 mg of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine XII-7a as a brownish solid. Yield: 32%

[0249] Step-2: Synthesis of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-7 The resulting 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine XII-7a (150 mg, 0.51 mmol) was dissolved in acetonitrile (5 mL) and treated dropwise with chlorosulfonic acid (2 mL, 2.91 mmol). The mixture was refluxed for 3 h, cooled to room temperature, hydrolyzed with ice water (50 mL) and neutralized with a saturated solution of sodium bicarbonate. The crude product was extracted with dichloromethane (three times, 50 mL each). The combined organic extracts were dried over MgSO4, filtered and concentrated. The resulting material was purified by column chromatography (eluent: pure dichloromethane) to give 163 mg of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-7 as a yellowish solid.

[0250] Yield: 81% 1H NMR (600 MHz, CDCl3) δ: 8.48 (s, 1H), 8.32 (d, J = 7.8 Hz, 2H), 8.18 (d, J = 8.3 Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.60 (t, J = 7.9 Hz, 2H), 7.41 (d, J = 8.4 Hz, 1H).

[0251] D. Synthesis of intermediates of formula XIII D.1. Synthesis of N-(4-bromo-2,5-difluoro-phenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-1: [ka]

[0252] Step-1: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1a

[0253] A mixture of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 (1.56 g, 4 mmol) and 4-bromo-2,5-difluoroaniline (998 mg, 4.8 mmol) in pyridine (8 mL) was stirred at room temperature for 2 h. The reaction was then quenched by adding 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as solvent to give 2.2 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1a as an off-white solid.

[0254] Yield: 80%. 1H NMR (600 MHz, DMSO-d6) δ 10.87 (s, 1H), 8.51 (s, 1H), 8.15 - 8.09 (m, 2H), 7.99 (d, J = 1.8 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.77 (t, J = 7.5 Hz, 1H), 7.63 - 7.59 (m, 2H), 7.56 (dd, J = 9.6, 6.3 Hz, 1H), 7.50 (dd, J = 8.6, 1.8 Hz, 1H), 7.34 (dd, J = 9.5, 6.8 Hz, 1H).

[0255] Step-2: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1b N-(4-Bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1a (1.12 g, 2 mmol) and N,N-diisopropylethylamine (DIPEA) (0.4 mL, 2.4 mmol) were dissolved in dry dichloromethane (25 mL). The solution was stirred at room temperature under argon atmosphere for 30 min, then chloromethyl methyl ether (0.2 mL, 2.4 mmol) was added. After stirring at room temperature for 16 h, the mixture was concentrated under reduced pressure. The residue thus obtained was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and evaporated to dryness. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 1.2 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1b as a yellowish solid.

[0256] Yield: 80%. 1H NMR (600 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.20 (dd, J = 8.6, 1.3 Hz, 2H), 8.03 (d, J = 1.8 Hz, 1H), 7.83 - 7.79 (m, 1H), 7.77 (dd, J = 9.2, 6.3 Hz, 1H), 7.70 - 7.64 (m, 2H), 7.52 (d, J = 8.6 Hz, 1H), 7.44 (dd, J = 8.6, 1.8 Hz, 1H), 7.32 (dd, J = 8.8, 6.4 Hz, 1H), 4.99 (s, 2H), 3.24 (s, 3H).

[0257] Step-3: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-1 N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-1b (910 mg, 1.5 mmol) was dissolved in THF (25 mL), treated with tetra-n-butylammonium fluoride (TBAF, 1.0 M in THF, 7.5 mL, 7.5 mmol) and stirred under reflux for 2 h. The reaction mixture was then quenched with 1 M HCl (10 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were dried over magnesium sulfate and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as solvent to give 0.69 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-1 as a colorless solid.

[0258] Yield: 79%. Neutral LCMS Method 2 (ES + ):482 / 484(M+18) + , 95% purity. 1H NMR (600 MHz, DMSO-d6) δ 12.28 (s, 1H), 7.99 (s, 1H), 7.81 (dd, J = 9.2, 6.3 Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 7.24 - 7.17 (m, 2H), 4.95 (s, 2H), 3.26 (s, 3H).

[0259] D.2. Synthesis of N-(4-difluoromethoxy-2,5-difluoro-phenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-2: [ka]

[0260] Step-1: Synthesis of 6-chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2a A mixture of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 (1.17 g, 3 mmol) and 4-(difluoromethoxy)-2,5-difluoroaniline (703 mg, 3.6 mmol) in pyridine (8 mL) was stirred at room temperature for 2 h. The reaction was then quenched by adding 30 mL of 1 M HCl and extracted three times with ethyl acetate (3x 50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as solvent to give 1.5 g of 6-chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2a as an off-white solid. This compound was used directly in the next step without further characterization. Yield: 91%.

[0261] Step-2: Synthesis of 6-chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2b 6-Chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2a (1.38 g, 2.5 mmol) and DIPEA (0.5 mL, 3 mmol) were suspended in 25 mL of dry dichloromethane under Ar atmosphere. After stirring at room temperature for 30 min, chloromethyl methyl ether (0.25 mL, 3 mmol) was added. The mixture was stirred at room temperature for 16 h. Subsequently, all volatiles were removed under reduced pressure. The residue was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and evaporated to dryness. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 1.18 g of 6-chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2b as an off-white solid.

[0262] Yield: 80%. The compound was used directly in the next step without further characterization.

[0263] Step-3: Synthesis of N-(4-difluoromethoxy-2,5-difluoro-phenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-2 6-Chloro-N-(4-(difluoromethoxy)-2,5-difluorophenyl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-2b (593 mg, 1 mmol) was dissolved in THF (25 mL), treated with TBAF (1.0 M) in THF (7.5 mL, 7.5 mmol) and stirred under reflux for 2 h. The reaction mixture was quenched with 1 M HCl (10 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to dryness. The crude material was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 0.34 g of N-(4-difluoromethoxy-2,5-difluoro-phenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-2 as a colorless solid.

[0264] Yield: 76%. Neutral LCMS Method 2 (ES + ): 470(M+18) + , 82% purity. 1 H NMR (600 MHz, DMSO-d6) δ 12.27 (s, 1H), 7.99 (s, 1H), 7.57 (d, J = 1.9 Hz, 1H), 7.47 - 7.40 (m, 2H), 7.25 (dd, J = 10.7, 6.9 Hz, 1H), 7.18 (dd, J = 8.7, 1.8 Hz, 1H), 4.95 (s, 2H), 3.27 (s, 3H). Missing 1H

[0265] D.3. Synthesis of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-3: [ka]

[0266] Step-1: Synthesis of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3a A mixture of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 (886 mg, 2.2 mmol) and 6-chloro-5-fluoro-2-methoxy-pyridin-3-amine X-1 (400 mg, 2.2 mmol) in pyridine (5 mL) was stirred at room temperature for 1.5 h. The mixture was quenched by addition of 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 0.7 g of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3a as an off-white solid.

[0267] Yield: 60%. This compound was used directly in the next step without further characterization.

[0268] Step-2: Synthesis of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3b 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3a (700 mg, 1.3 mmol) and DIPEA (0.27 mL, 1.6 mmol) were dissolved in dry dichloromethane (25 mL). After stirring at room temperature under Ar for 30 min, chloromethyl methyl ether (0.13 mL, 1.6 mmol, 1.2 equiv.) was added. The mixture was stirred at room temperature for 16 h. The volatile components were then removed under reduced pressure. The residue was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate and evaporated to dryness. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 0.59 g of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3b as an off-white solid.

[0269] Yield: 80%. This compound was used directly in the next step without further characterization.

[0270] Step-3: Synthesis of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-3 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-3b (574 mg, 1 mmol) was dissolved in THF (25 mL), treated with TBAF (1.0 M in THF, 7.5 mL, 7.5 mmol) and stirred under reflux for 2 h. The reaction mixture was then quenched with 1 M HCl (10 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to dryness. The crude product was purified by column chromatography using petroleum ether:ethyl acetate (80:20) to give 0.33 g of 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-3 as a colorless solid.

[0271] Yield: 76%. Neutral LCMS Method 2 (ES + ):434(M+H) + , 94% purity. 1 H NMR (600 MHz, DMSO-d6) δ 12.19 (s, 1H), 7.94 (s, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.19 (dd, J = 8.6, 1.9 Hz, 1H), 4.93 (s, 2H), 3.28 (s, 3H), 3.24 (s, 3H).

[0272] D.4. Synthesis of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4: [ka]

[0273] Step-1: Synthesis of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4a A mixture of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-7 (438 mg, 1.1 mmol) and 6-(difluoromethoxy)-5-fluoro-2-methoxy-pyridin-3-amine X-2 (272 mg, 1.3 mmol) in pyridine (5 mL) was stirred at room temperature for 3 h. The reaction mixture was then quenched by the addition of 1 M HCl (30 mL) and extracted three times with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as a solvent to give 0.37 g of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4a as an off-white powder.

[0274] Yield: 61%. Neutral LCMS Method 2 (ES + ):563(M+H) + , 76% purity.

[0275] Step-2: 6-Chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4b 6-Chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4a (365 mg, 0.65 mmol) and DIPEA (0.13 mL, 0.78 mmol) were dissolved in dry dichloromethane (25 mL) under argon atmosphere. The solution was stirred at room temperature for 30 min, then chloromethyl methyl ether (0.06 mL, 0.78 mmol) was added. After stirring at room temperature for 18 h, the volatile components were removed under reduced pressure. The residue was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give 0.30 g of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4b as a yellow powder.

[0276] Yield: 76%. This compound was used directly in the next step without further characterization.

[0277] Step-3: Synthesis of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4 6-Chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4b (273 mg, 0.45 mmol) was dissolved in THF (25 mL), treated with TBAF 1.0 M in THF (2.25 mL, 2.25 mmol) and stirred under reflux for 4 h. After addition of 1 M HCl (10 mL), the mixture was extracted with ethyl acetate (2x50 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as solvent to give 0.98 g of 6-chloro-N-(6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl)-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-4 as a white powder. Yield: 47%.

[0278] D.5. Synthesis of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-5: [ka]

[0279] Step-1: Synthesis of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5a A mixture of 1-(benzenesulfonyl)-6-chloro-indole-3-sulfonyl chloride XII-6 (390 mg, 1 mmol) and 5-bromo-6-methoxypyridin-2-amine (244 mg, 1.2 mmol) in pyridine (5 mL) was stirred at room temperature for 1 h. Subsequently, the mixture was quenched with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated to dryness. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as solvent to give 0.39 g of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5a as an off-white solid.

[0280] Yield: 70%. Neutral LCMS Method 2 (ES + ):556 / 558(M+H) + , 91% purity.

[0281] Step-2: Synthesis of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5b N-(5-Bromo-6-methoxypyridin-2-yl)-6-chloro-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5a (380 mg, 0.68 mmol) and DIPEA (0.1 mL, 0.8 mmol) were dissolved in 25 mL of dry dichloromethane under Ar atmosphere. The solution was stirred at room temperature for 30 min, then chloromethyl methyl ether (0.06 mL, 0.8 mmol, 1.2 equiv.) was added. After stirring at room temperature for a further 18 h, the volatile components were removed under reduced pressure. The residue thus obtained was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as eluent to give 0.28 g of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5b as an off-white solid.

[0282] Yield: 69%. Neutral LCMS Method 2 (ES + ):600 / 602(M+H) + , 90% purity. 1 H NMR (600 MHz, DMSO-d6) δ 8.63 (s, 1H), 8.17 (dd, J = 8.5, 1.0 Hz, 2H), 8.04 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 1.8 Hz, 1H), 7.78 (t, J = 7.5 Hz, 1H), 7.67 - 7.61 (m, 2H), 7.44 - 7.35 (m, 2H), 7.05 (d, J = 8.1 Hz, 1H), 5.28 (s, 2H), 3.27 (s, 3H), 3.14 (s, 3H).

[0283] Step-3: Synthesis of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-5 N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-indole-3-sulfonamide XIII-5b (280 mg, 0.46 mmol) was dissolved in THF (25 mL), treated with TBAF (1.0 M in THF, 2.3 mL, 2.3 mmol) and stirred under reflux for 2 h. The reaction mixture was then quenched with 10 mL of 1 M HCl and extracted with ethyl acetate (2×50 mL). The combined organic extracts were dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) as solvent to give 0.16 g of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-5 as a white solid.

[0284] Yield: 76%. This compound was used directly in the next step without further characterization.

[0285] D.6. Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6: [ka]

[0286] Step-1: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6a A mixture of 1-(benzenesulfonyl)-6-chloro-pyrrolo[2,3-b]pyridine-3-sulfonyl chloride XII-7 (390 mg, 1 mmol) and 4-bromo-2,5-difluoroaniline (248 mg, 1.2 mmol) in pyridine (5 mL) was stirred at room temperature for 2 h, followed by quenching by addition of 1 M HCl (30 mL) and extraction with ethyl acetate (3×50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as solvent to give 0.54 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6a as an off-white solid.

[0287] Yield: 80%. Neutral LCMS Method 2 (ES + ):562 / 564(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.84 (s, 1H), 8.42 (d, J = 1.2 Hz, 1H), 8.20 (dd, J = 8.4, 1.2 Hz, 1H), 8.15 - 8.09 (m, 2H), 7.80 (td, J = 7.5, 1.2 Hz, 1H), 7.72 - 7.54 (m, 4H), 7.37 (dd, J = 9.4, 6.8 Hz, 1H).

[0288] Step-2: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6b N-(4-Bromo-2,5-difluorophenyl)-6-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6a (400 mg, 0.7 mmol) and DIPEA (0.14 mL, 0.84 mmol) were dissolved in 25 mL of dry dichloromethane under an argon atmosphere. The solution was stirred at room temperature for 30 min, then chloromethyl methyl ether (0.06 mL, 0.84 mmol) was added. After stirring at room temperature for a further 18 h, the volatile components were removed under reduced pressure. The residue thus obtained was treated with 1 M HCl (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography using petroleum ether:ethyl acetate (85:15) as eluent to give 0.27 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6b as an off-white solid.

[0289] Yield: 65%. This compound was used directly in the next step without further characterization.

[0290] Step-3: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6 N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6b (250 mg, 0.41 mmol) was dissolved in THF (25 mL), treated with TBAF 1.0 M in THF (2.05 mL, 2.05 mmol) and stirred under reflux for 2 h. The reaction mixture was then quenched with 10 mL of 1 M HCl, extracted twice with ethyl acetate (100 mL), dried over magnesium sulfate and evaporated to dryness. The crude residue was purified by column chromatography using petroleum ether:ethyl acetate (80:20) to give 0.12 g of N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide XIII-6 as a colorless solid.

[0291] Yield: 63%. Neutral LCMS Method 2 (ES + ):466 / 468(M+H) + , 94% purity. This compound was used in the subsequent alkylation step without further characterization.

[0292] Example Compounds E. Synthesis of Compounds of Formula I All compounds of the invention specifically disclosed herein are designated "I-x," where any "x" refers to a number that identifies the individual compound. Thus, example compounds are designated I-1, I-2, I-3, etc. This is regardless of whether any compound can also be described by any subformula herein, such as formula II, III, or IV.

[0293] E.1. Method A. Synthesis of 6-chloro-N-(4-cyano-2-fluorophenyl)-1-methylindole-3-sulfonamide I-1 [ka]

[0294] To a solution of 6-chloro-1-methyl-1H-indole-3-sulfonyl chloride XII-1 (0.40 g, 1.52 mmol) in pyridine (15 mL), 4-amino-3-fluoro-benzonitrile (0.23 g, 1.67 mmol) was added and the reaction mixture was heated at 80 °C for 3 h. The progress of the reaction was monitored by TLC and LCMS. After completion, the reaction mixture was concentrated in vacuum. The residue was diluted with H2O (15 mL) and extracted with EtOAc (2 x 30 mL). The organic layer was separated, washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated in vacuum. The resulting crude product was purified by column chromatography (silica, 100-200 mesh, 3% EtOAc in hexane) to give 6-chloro-N-(4-cyano-2-fluorophenyl)-1-methylindole-3-sulfonamide I-1 (0.05 g) as an off-white solid.

[0295] Yield: 9%. Basic LCMS Method 1 (ES - ):362(M-H) - , 98% purity. 1 H NMR (400 MHz, DMSO-d6) δ 3.82 (s, 3H) 7.28 (d, J=7.34 Hz, 1H) 7.55 - 7.60 (m, 2H) 7.72 - 7.79 (m, 2H) 7.83 (d, J=8.31 ​​Hz, 1H) 8.20 (s, 1H) 10.87 (s, 1H).

[0296] The following compounds in Table 1 can be synthesized following a method similar to Method A. [Table 1]

[0297] 6-Chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-1-methylindole-3-sulfonamide I-2 [ka]

[0298] Basic LCMS Method 1 (ES - ): 402 (M-H) - , 100% purity. 1 H NMR (400 MHz, DMSO-d6) δ 3.65 (s, 3H) 3.85 (s, 3H) 7.25-7.28 (m, 1H) 7.73 (d, J=1.47 Hz, 1H) 7.83-7.87 (m, 1H) 7.92-7.95 (m, 1H) 8.23-8.24 (m, 1H) 11.15 (s, 1H).

[0299] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide I-3 [ka]

[0300] Neutral LCMS Method 2 (ES + ):436(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.28 (s, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.62 (dd, J = 9.6, 6.3 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.33 (dd, J = 9.8, 6.8 Hz, 1H), 3.80 (s, 3H).

[0301] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide I-4 [ka]

[0302] Neutral LCMS Method 2 (ES + ):424(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.24 (s, 1H), 8.12 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.36-7.29 (m, 2H), 7.16 (t, J = 72.7 Hz, 1H), 3.80 (s, 3H).

[0303] 6-Chloro-1-(2,2-difluoroethyl)-N-[4-(difluoromethoxy)-2,5-difluorophenyl]pyrrolo[2,3-b]pyridine-3-sulfonamide I-5 [ka]

[0304] Neutral LCMS Method 2 (ES + ):474(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.47 (s, 1H), 8.17 (s, 1H), 8.15 (d, J = 8.3 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.31-7.29 (m, 2H), 7.15 (t, J = 72.8 Hz, 1H), 6.39 (tt, J = 54.6 Hz, J = 3.3 Hz, 1H), 4.74 (td, J = 15.7 Hz, 3.3 Hz, 2H).

[0305] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,2-difluoroethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-6 [ka]

[0306] Neutral LCMS Method 2 (ES + ):486(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.22 (d, J = 8.2 Hz, 1H), 8.22 (s, 1H), 7.61 (dd, J = 9.7, 6.4 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.28 (dd, J = 9.7, 6.7 Hz, 1H), 6.40 (t, J = 54.5 Hz, 1H), 4.74 (t, J = 15.3 Hz, 2H).

[0307] E.2. Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)indole-3-sulfonamide I-7 [ka]

[0308] Step-1: Synthesis of methyl 3-[3-[(4-bromo-2,5-difluoro-phenyl)sulfamoyl]-6-chloro-indol-1-yl]-2-fluoro-propanoate I-7a A mixture of methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-indol-1-yl)-2-fluoropropanoate XII-4 (240 mg, 0.68 mmol), pyridine (3.0 mL), DMAP (8.3 mg, 0.068 mmol) and 4-bromo-2,5-difluoroaniline (170 mg, 0.82 mmol) was stirred at 70° C. overnight. After removing the solvent under reduced pressure, the residue was extracted with EtOAc (50 mL) and washed with brine. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure to give methyl 3-[3-[(4-bromo-2,5-difluoro-phenyl)sulfamoyl]-6-chloro-indol-1-yl]-2-fluoropropanoate I-7a (143 mg), which was used directly in the next step without further purification or characterization. Yield: 40%.

[0309] Step-2: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)indole-3-sulfonamide I-7 To methyl 3-[3-[(4-bromo-2,5-difluoro-phenyl)sulfamoyl]-6-chloro-indol-1-yl]-2-fluoro-propanoate I-7a (26 mg, 0.05 mmol) in THF was added LiAlH4 (3.0 mg, 0.6 mmol) at 0 °C. The mixture was stirred overnight at 0 °C, quenched with H2O (5.0 mL), and extracted with EtOAc (20 mL). The organic phase was washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)indole-3-sulfonamide I-7 as colorless crystals (18 mg).

[0310] Yield: 72%. Neutral LCMS Method 2 (ES + ):497(M+H) + , 96% purity. 1H NMR (600 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.08 (s, 1H), 7.85 - 7.72 (m, 2H), 7.61 (dd, J = 9.6, 6.4 Hz, 1H), 7.33 - 7.23 (m, 2H), 5.15 (s, 1H), 4.85 - 4.67 (m, 1H), 4.64 - 4.42 (m, 2H), 3.54 (dddd, J = 55.9, 24.4, 12.4, 4.4 Hz, 2H).

[0311] E.3. Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-8 [ka]

[0312] Step-1: Synthesis of 3-(3-(N-(4-bromo-2,5-difluorophenyl)sulfamoyl)-6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoromethylpropanoate I-8a Methyl 3-(6-chloro-3-(chlorosulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate XII-4 (225 mg, 0.64 mmol), pyridine (3.0 mL), DMAP (7.8 mg, 0.064 mmol) and 4-bromo-2,5-difluoroaniline (158 mg, 0.77 mmol) were stirred at 70° C. overnight. After removing the solvent under reduced pressure, the residue was extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure to give methyl 3-(3-(N-(4-bromo-2,5-difluorophenyl)sulfamoyl)-6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate I-8a (189 mg). The crude intermediate was used directly in the next step without further purification or characterization. Yield: 56%.

[0313] Step-2: Synthesis of N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-8 To a solution of methyl 3-(3-(N-(4-bromo-2,5-difluorophenyl)sulfamoyl)-6-chloro-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-fluoropropanoate I-8a (43 mg, 0.08 mmol) in THF was added LiAlH4 (4 mg, 0.9 mmol) at 0 °C. The mixture was stirred at the same temperature overnight, then quenched with H2O (5.0 mL) and extracted with EtOAc (20 mL). The organic phase was washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-8 as colorless crystals (25 mg).

[0314] Yield: 62%. Neutral LCMS Method 2 (ES + ):498(M+H) + , 92% purity. 1 H NMR (600 MHz, DMSO-d6) δ 8.08 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 1.1 Hz, 1H), 7.46 (dd, J = 9.1, 6.9 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.15 (dd, J = 9.2, 6.0 Hz, 1H), 6.84 (d, J = 2.8 Hz, 1H), 4.98 - 4.77 (m, 1H), 4.69 - 4.50 (m, 2H), 3.71 - 3.54 (m, 2H), 2.68 (s, 1H).

[0315] E.4. Method B. Synthesis of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-1-(2-hydroxyethyl)indole-3-sulfonamide I-9 [ka]

[0316] To a solution of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide XIII-5 (0.16 g, 0.35 mmol) in dry dimethyl sulfoxide (5 mL) at 0 °C was added powdered potassium hydroxide (90 mg, 1.57 mmol). The mixture was stirred at 0 °C for 15 min and treated dropwise with 2-iodoethanol (90 mg, 0.52 mmol, 1.5 equiv). After heating at 60 °C for 16 h, the resulting mixture was poured into ice water and extracted with ethyl acetate (3 × 50 mL). The combined organic extracts were washed with brine, dried over MgSO4, filtered, and concentrated under vacuum. The residue was subsequently dissolved in methanol (15 mL), treated with concentrated HCl (5 equiv), and stirred for 16 h. The solvent was removed under reduced pressure and the residue was treated with ethyl acetate (50 mL) and a saturated solution of sodium bicarbonate (50 mL). The organic layer was separated and the aqueous phase was extracted twice with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under vacuum. Purification was carried out by column chromatography on silica gel using a mixture of petroleum ether:ethyl acetate (gradient, 80:20 to 50:50) as eluent to give 33 mg of N-(5-bromo-6-methoxypyridin-2-yl)-6-chloro-1-(2-hydroxyethyl)indole-3-sulfonamide I-9 as a white solid.

[0317] Yield: 21%. Neutral LCMS Method 2 (ES + ):462(M+H) + , 100% purity.

[0318] The following compounds in Table 2 can be synthesized following a method similar to Method B. [Table 2]

[0319] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)indole-3-sulfonamide: I-10 [ka]

[0320] Neutral LCMS Method 2 (ES + ):465 / 467(M+H) + , 97% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.49 (s, 1H), 8.06 (s, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.60 (dd, J = 9.7, 6.3 Hz, 1H), 7.28 (dd, J = 9.9, 6.8 Hz, 1H), 7.24 (dd, J = 8.5, 1.9 Hz, 1H), 4.87 (t, J = 5.2 Hz, 1H), 4.26 (t, J = 5.2 Hz, 2H), 3.66 (q, J = 5.2 Hz, 2H).

[0321] 2-[3-[(4-Bromo-2,5-difluorophenyl)sulfamoyl]-6-chloroindol-1-yl]acetic acid I-11 [ka]

[0322] Neutral LCMS Method 2 (ES + ):479(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.09 (s, 1H), 7.79 (d, J = 8.6 Hz, 1H), 7.73 (s, 1H), 7.60 (dd, J = 9.6, 6.4 Hz, 1H), 7.30 - 7.21 (m, 2H), 5.10 (s, 2H).

[0323] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylindole-3-sulfonamide I-12 [ka]

[0324] Neutral LCMS Method 2 (ES + ):435(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.48 (d, J = 10.3 Hz, 1H), 8.09 (s, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.59 (dd, J = 9.7, 6.4 Hz, 1H), 7.31 (dd, J = 9.9, 6.9 Hz, 1H), 7.26 (dd, J = 8.6, 1.9 Hz, 1H), 3.80 (s, 3H).

[0325] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-chloroethyl)indole-3-sulfonamide: I-13 [ka]

[0326] Neutral LCMS Method 2 (ES + ):483 / 485(M+H) + , 96% purity. 1H NMR (600 MHz, DMSO-d6) δ 10.51 (s, 1H), 8.13 (s, 1H), 7.87 - 7.84 (m, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.57 (dd, J = 9.6, 6.4 Hz, 1H), 7.30 - 7.23 (m, 2H), 4.59 (t, J = 5.6 Hz, 2H), 3.95 (t, J = 5.6 Hz, 2H).

[0327] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3-hydroxypropyl)indole-3-sulfonamide: I-14 [ka]

[0328] Neutral LCMS Method 2 (ES + ):479 / 481(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.45 (s, 1H), 8.08 (s, 1H), 7.80 - 7.73 (m, 2H), 7.58 (dd, J = 9.6, 6.4 Hz, 1H), 7.30 - 7.21 (m, 2H), 4.60 (t, J = 5.1 Hz, 1H), 4.26 (t, J = 6.8 Hz, 2H), 3.25 (q, J = 5.7 Hz, 2H), 1.82 (p, J = 6.5 Hz, 2H).

[0329] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-[2-(dimethylamino)ethyl]indole-3-sulfonamide I-15 [ka]

[0330] Neutral LCMS Method 2 (ES + ):492 / 494(M+H)+ , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.81 - 7.77 (m, 2H), 7.55 (dd, J = 9.7, 6.4 Hz, 1H), 7.28 - 7.22 (m, 2H), 4.29 (t, J = 6.0 Hz, 2H), 2.58 (t, J = 6.0 Hz, 2H), 2.12 (s, 3H), 1.39 (s, 3H), NH Not observed.

[0331] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-[2-(2-hydroxyethoxy)ethyl]indole-3-sulfonamide I-16 [ka]

[0332] Neutral LCMS Method 2 (ES + ):509 / 511(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.08 (s, 1H), 7.82 - 7.77 (m, 2H), 7.59 (dd, J = 9.6, 6.4 Hz, 1H), 7.31 - 7.23 (m, 2H), 4.54 (t, J = 5.4 Hz, 1H), 4.37 (t, J = 5.1 Hz, 2H), 3.68 (t, J = 5.1 Hz, 2H), 3.37 (t, J = 5.4 Hz, 2H), 3.31 (d, J = 4.7 Hz, 2H).

[0333] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-oxopropyl)indole-3-sulfonamide I-17 [ka]

[0334] Neutral LCMS Method 2 (ES + ):477 / 479(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.53 (s, 1H), 7.94 (s, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 1.8 Hz, 1H), 7.61 (dd, J = 9.6, 6.3 Hz, 1H), 7.28 - 7.22 (m, 2H), 5.26 (s, 2H), 2.17 (s, 3H).

[0335] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxypropyl)indole-3-sulfonamide I-18 [ka]

[0336] Neutral LCMS Method 2 (ES + ):479 / 481(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.49 (s, 1H), 8.02 (s, 1H), 7.77 (d, J = 8.7 Hz, 2H), 7.58 (dd, J = 9.7, 6.3 Hz, 1H), 7.27 (dd, J = 9.9, 6.8 Hz, 1H), 7.23 (dd, J = 8.5, 1.9 Hz, 1H), 4.88 (d, J = 4.9 Hz, 1H), 4.19 (dd, J = 14.1, 4.0 Hz, 2H), 4.05 (dd, J = 14.2, 7.1 Hz, 1H), 0.97 (d, J = 6.2 Hz, 3H).

[0337] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide I-19 [ka]

[0338] Neutral LCMS Method 2 (ES + ):497 / 499(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.51 (s, 1H), 8.03 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.59 (dd, J = 9.6, 6.3 Hz, 1H), 7.31 - 7.22 (m, 2H), 5.44 (d, J = 5.6 Hz, 1H), 4.39 - 4.32 (m, 2H), 4.32 - 4.27 (m, 1H), 4.20 (ddd, J = 22.5, 12.0, 6.6 Hz, 2H).

[0339] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3,3,3-trifluoro-2-hydroxypropyl)indole-3-sulfonamide I-20 [ka]

[0340] Neutral LCMS Method 2 (ES + ):533(M+H) + , 94% purity. 1H NMR (600 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.12 (s, 1H), 7.82 - 7.75 (m, 2H), 7.59 (dd, J = 9.6, 6.4 Hz, 1H), 7.28 (d, J = 2.0 Hz, 2H), 6.60 (d, J = 6.3 Hz, 1H), 4.54 (d, J = 10.9 Hz, 1H), 4.43 - 4.35 (m, 2H).

[0341] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-hydroxyethyl)indole-3-sulfonamide I-21 [ka]

[0342] Neutral LCMS Method 2 (ES + ):453(M+H) + , 97% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.01 (s, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.31 - 7.26 (m, 2H), 7.22 (dd, J = 8.6, 1.8 Hz, 1H), 7.08 (d, J = 72.9 Hz, 1H), 4.88 (t, J = 5.2 Hz, 1H), 4.26 (t, J = 5.2 Hz, 2H), 3.66 (q, J = 5.2 Hz, 2H).

[0343] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylindole-3-sulfonamide I-22 [ka]

[0344] Neutral LCMS Method 2 (ES+ ):423(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.05 (s, 1H), 7.74 - 7.69 (m, 2H), 7.33 - 7.28 (m, 2H), 7.24 (dd, J = 8.5, 1.9 Hz, 1H), 7.09 (d, J = 73.0 Hz, 1H), 3.80 (s, 3H).

[0345] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-ethylindole-3-sulfonamide I-23 [ka]

[0346] Neutral LCMS Method 2 (ES + ):437(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.29 (s, 1H), 8.08 (s, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.31 - 7.24 (m, 2H), 7.23 (dd, J = 8.6, 1.8 Hz, 1H), 7.08 (d, J = 72.8 Hz, 1H), 4.24 (q, J = 7.2 Hz, 2H), 1.29 (d, J = 7.2 Hz, 3H).

[0347] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-fluoroethyl)indole-3-sulfonamide I-24 [ka]

[0348] Neutral LCMS Method 2 (ES+ ):455(M+H) + , 97% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.34 (s, 1H), 8.05 (s, 1H), 7.81 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 8.6 Hz, 1H), 7.29 - 7.23 (m, 3H), 7.07 (d, J = 72.9 Hz, 1H), 4.62 - 4.73 (m, 2H), 4.53 - 4.62 (m, 2H).

[0349] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-propylindole-3-sulfonamide I-25 [ka]

[0350] Neutral LCMS Method 2 (ES + ):451(M+H) + , 99% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.30 (s, 1H), 8.05 (s, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.73 (d, J = 8.7 Hz, 1H), 7.27 (ddd, J = 10.5, 7.3, 3.2 Hz, 2H), 7.23 (dd, J = 8.6, 1.8 Hz, 1H), 7.07 (d, J = 72.8 Hz, 1H), 4.17 (t, J = 6.8 Hz, 2H), 1.68 (h, J = 7.2 Hz, 2H), 0.66 (t, J = 7.3 Hz, 3H).

[0351] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-methoxyethyl)indole-3-sulfonamide I-26 [ka]

[0352] Neutral LCMS Method 2 (ES + ):467(M+H) + , 97% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.35 (s, 1H), 7.99 (s, 1H), 7.79 (s, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.31 - 7.22 (m, 3H), 7.08 (d, J = 72.9 Hz, 1H), 4.38 (t, J = 5.1 Hz, 2H), 3.58 (t, J = 5.0 Hz, 2H), 3.12 (s, 3H).

[0353] 6-Chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2,3-dihydroxypropyl)indole-3-sulfonamide I-27 [ka]

[0354] Neutral LCMS Method 2 (ES + ):483(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.33 (s, 1H), 7.94 (s, 1H), 7.75 - 7.69 (m, 2H), 7.32 - 7.25 (m, 2H), 7.22 (d, J = 8.5 Hz, 1H), 7.08 (d, J = 72.9 Hz, 1H), 5.01 (d, J = 5.3 Hz, 1H), 4.79 (t, J = 5.6 Hz, 1H), 4.31 - 4.09 (m, 2H), 3.72 (s, 1H), 3.18 (dt, J = 10.6, 6.2 Hz, 2H).

[0355] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)indole-3-sulfonamide I-28 [ka]

[0356] Neutral LCMS Method 2 (ES + ):495 / 497(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.00 (s, 1H), 7.77 (d, J = 8.6 Hz, 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.59 (dd, J = 9.6, 6.4 Hz, 1H), 7.31 - 7.21 (m, 2H), 5.00 (d, J = 5.2 Hz, 1H), 4.32 (dd, J = 14.3, 3.5 Hz, 1H), 4.11 (dd, J = 14.4, 7.3 Hz, 1H), 3.38 - 3.35 (m, 2H), 3.26 - 3.15 (m, 2H).

[0357] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-29 [ka]

[0358] Neutral LCMS Method 2 (ES + ):496 / 498(M+H) + , 99% purity. 1H NMR (600 MHz, DMSO-d6) δ 10.55 (s, 1H), 8.22 - 8.12 (m, 2H), 7.63 - 7.56 (m, 1H), 7.39 (dd, J = 8.3, 1.1 Hz, 1H), 7.29 (ddd, J = 9.8, 6.8, 1.1 Hz, 1H), 5.01 - 4.95 (m, 1H), 4.76 (t, J = 5.5 Hz, 1H), 4.40 (dd, J = 13.9, 3.8 Hz, 1H), 4.16 - 3.77 (m, 2H), 3.34 (d, J = 1.2Hz, 2H).

[0359] N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-30 [ka]

[0360] Neutral LCMS Method 2 (ES + ):466 / 468(M+H) + , 98% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.67 - 10.33 (m, 1H), 8.22 (s, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.62 (dd, J = 9.6, 6.4 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.30 (dd, J = 9.7, 6.8 Hz, 1H), 4.92 - 4.86 (m, 1H), 4.31 - 4.25 (m, 2H), 3.74 - 3.69 (m, 2H).

[0361] 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-methylindole-3-sulfonamide I-31 [ka]

[0362] Neutral LCMS Method 2 (ES + ):404(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.14 (s, 1H), 8.11 (s, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.72 - 7.68 (m, 2H), 7.26 (dd, J = 8.6, 1.9 Hz, 1H), 3.80 (s, 3H), 3.54 (s, 3H).

[0363] 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)indole-3-sulfonamide I-32 [ka]

[0364] Neutral LCMS Method 2 (ES + ):454(M+H) + , 99% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.05 (s, 1H), 7.87 - 7.78 (m, 2H), 7.68 (d, J = 9.0 Hz, 1H), 7.29 (dd, J = 8.6, 1.8 Hz, 1H), 6.37 (tt, J = 54.6, 3.2 Hz, 1H), 4.78 (td, J = 15.8, 3.2 Hz, 2H), 3.46 (d, J = 0.6 Hz, 3H).

[0365] 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide I-33 [ka]

[0366] Neutral LCMS Method 2 (ES + ):466(M+H) + , 95% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.14 (s, 1H), 8.04 (s, 1H), 7.79 (dd, J = 15.4, 5.1 Hz, 2H), 7.66 (d, J = 9.3 Hz, 1H), 7.25 (dd, J = 8.5, 1.7 Hz, 1H), 5.42 (d, J = 5.6 Hz, 1H), 4.41 - 4.29 (m, 2H), 4.29 - 4.14 (m, 2H), 3.55 (s, 3H), 3.35 (s, 1H).

[0367] 6-Chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,3-dihydroxypropyl)indole-3-sulfonamide I-34 [ka]

[0368] Neutral LCMS Method 2 (ES + ):464(M+H) + , 99% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.11 (s, 1H), 8.02 (s, 1H), 7.82 - 7.78 (m, 1H), 7.72 (d, J = 1.6 Hz, 1H), 7.67 (d, J = 9.1 Hz, 1H), 7.24 (dd, J = 8.5, 1.9 Hz, 1H), 4.98 (d, J = 5.3 Hz, 1H), 4.78 (dd, J = 6.0, 5.1 Hz, 1H), 4.35 - 4.07 (m, 2H), 3.55 (s, 3H), 3.38 - 3.31 (m, 2H), 3.23 - 3.16 (m, 1H).

[0369] 6-Chloro-N-[6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl]-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide I-35 [ka]

[0370] Neutral LCMS Method 2 (ES + ):467(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 9.94 (s, 1H), 8.16 - 8.14 (m, 1H), 8.09 (s, 1H), 7.75 - 7.72 (m, 1H), 7.51 (d, J = 72.1 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 4.90 (t, J = 5.3 Hz, 1H), 4.27 (t, J = 5.5 Hz, 2H), 3.71 (q, J = 5.5 Hz, 2H), 3.37 (s, 3H).

[0371] E.5. Synthesis of 1-(2-azidoethyl)-N-(4-bromo-2,5-difluorophenyl)-6-chloroindole-3-sulfonamide I-36 [ka]

[0372] A solution of I-13a (200 mg, 0.38 mmol) in 5 mL of dry dimethyl sulfoxide was treated with potassium iodide (75 mg, 0.45 mmol) and sodium azide (30 mg, 0.45 mmol) and heated at 80° C. for 16 h. The mixture was poured into ice water and the precipitate was filtered under reduced pressure to give 1-(2-azidoethyl)-N-(4-bromo-2,5-difluorophenyl)-6-chloro-N-(methoxymethyl)-1H-indole-3-sulfonamide, which was characterized only by TLC (one clear spot of product) and used directly in the next step. The intermediate thus obtained was dissolved in methanol (15 mL), treated with concentrated HCl (5 equiv.) and stirred for 16 h. The solvent was removed under reduced pressure and the residue was treated with ethyl acetate (50 mL) and a saturated solution of sodium bicarbonate (50 mL). The organic layer was separated and the aqueous phase was extracted with ethyl acetate (2x50 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give 140 mg of 1-(2-azidoethyl)-N-(4-bromo-2,5-difluorophenyl)-6-chloroindole-3-sulfonamide I-36 as a colorless solid.

[0373] Yield: 75% in two steps. Neutral LCMS Method 2 (ES + ): 490 / 492(M+H) + , 96% purity. 1 H NMR (600 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.13 (s, 1H), 7.85 (d, J = 1.9 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.57 (dd, J = 9.7, 6.4 Hz, 1H), 7.30 - 7.24 (m, 2H), 4.42 (t, J = 5.6 Hz, 2H), 3.74 - 3.66 (m, 2H).

[0374] Further examples Additional compounds can be prepared according to the routes described herein. Examples can be prepared by these methods using various indoles or azaindoles as starting materials. For example, instead of the 6-chloroindole and 6-chloro-1H-pyrrolo[2,3-b]pyridine used in the synthesis of certain examples above, corresponding starting compounds with other residues at the R6 position can be used. Non-limiting examples of such starting materials are 6-(difluoromethyl)-1H-pyrrolo[2,3-b]pyridine, 6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine, 6-bromo-pyrrolo[2,3-b]pyridine, 6-(difluoromethoxy)-1H-indole, 6-bromo-1H-indole, 6-cyclopropyl-1H-indole or 1H-indole-6-carbonitrile, which are further described in WO2018 / 122232 and WO2019 / 243303.

[0375] In one embodiment, additional examples are provided as described in the general method below: (i) first introducing a protecting group P1 into a compound of formula XIII-P2 according to the general scheme, then removing the group P2 to obtain a compound of structure XIII-P1: [ka] And, as further exemplified herein, compounds of formula XIII-P1 can then be synthesized by (ii) alkylating a compound of formula XIII-P1 with a hydroxyethyl halide (such as hydroxyethyl iodide), where P1 is a protecting group such as methoxymethyl (as exemplified for I-9, I-21, I-30, I-35) according to the following scheme: [ka] In the formula, R2, R4, R5, R6, R8, R10, R11, X1, X2 and X3 are as described herein.

[0376] Alternative compounds XIII-P2 suitable for use in this method, as well as their precursors and preparation routes, are described, for example, in WO2018-122232 and WO2019 / 243303.

[0377] The inventors of the present invention expect that the resulting compounds will have good GPR17 modulating activity, as described for other compounds herein.

[0378] Test the example and Ca 2+ and cAMP assay activities are reported in Table 3 below.

[0379] B. Biology / Pharmacology: B-I.Cell culture GPR17 recombinant cell line: Flp-In T-REx CHO cells stably expressing the human GPR17 receptor (CHO hGPR17) from the laboratory of Evi Kostenis (University of Bonn, Germany) were cultured at 37 °C in a humidified atmosphere of 5% CO2. Cells were cultured in DMEM containing nutrient mixture F-12 supplemented with hygromycin B (500 μg / ml) and blasticidin (30 μg / ml). Expression from the Flp-In locus was induced by treatment with doxycycline (1 μg / ml) for 16–20 h before assay.

[0380] Primary oligodendrocytes: Primary oligodendrocyte precursor cells (OPCs) were isolated from the forebrains of Wistar rat pups on postnatal days 0–2. The cerebrum was mechanically dissociated with a syringe and two different hollow needles (first 1.2x40 and then 0.60x30). The clump-free cell suspension was filtered through a 70 μm cell strainer and plated on poly-D-lysine-coated 75 cm plates with medium changes every 2 days with DMEM supplemented with 10% (v / v) heat-inactivated fetal bovine serum, penicillin (100 units / ml), and streptomycin (0.1 mg / ml). 2OPCs were plated in culture flasks. After 8–11 days at 37°C in a humidified atmosphere of 5% CO2, the mixed culture was shaken at 240 rpm for 14–24 h to separate the OPCs from the astrocytes and microglia. To further enrich for OPCs, the suspension was plated on uncoated Petri dishes for 45 min. OPCs were then seeded on poly-L-ornithine-coated plates and maintained at 37°C in a humidified atmosphere of 5% CO2 with medium changes every 2 days in growth Neurobasal medium supplemented with 2% (v / v) B27, 2 mM GlutaMAX, 100 units / ml penicillin, 0.1 mg / ml streptomycin, 10 ng / ml PDGF-AA, and 10 ng / ml basic FGF.

[0381] B-II: Functional in vitro GPR17 assay B-II-A: Calcium mobilization functional assay GPR17 is a G protein-coupled receptor. Activation of GPR17 triggers Gq-type G protein signaling, leading to upregulation of cytosolic endoplasmic reticulum calcium (Ca 2+ ) stores, which releases cytosolic Ca 2+ The levels of calcium in the blood can be measured using calcium 5 dye, a fluorescent indicator dye for calcium levels, as described further below. 2+ The antibodies were assessed in either the GPR17 cAMP assay or the GPR17 cAMP assay. As shown in Table 3 below, several representative examples were measured in both activity tests.

[0382] Ca 2+ Assay Description: CHO hGPR17 were thawed and seeded into black, clear-bottom 384-well plates at a density of 20,000 cells per well. Cells were incubated overnight at 37 °C in a humidified atmosphere of 5% CO2. 16–20 h after seeding, CHO hGPR17 were enriched in cytosolic Ca 2+ The indicator fluorescent dye, calcium 5 dye, was loaded for 60 min according to the manufacturer's instructions. 2+The fluorescence signal versus concentration was recorded over time on a FLIPR Tetra reader at room temperature. Cells were first treated with increasing concentrations of test compounds (usually 10 -11 M to 10 -6 The cells were incubated in HBSS Hepes buffer pH 7.4 containing 100 mM M for 30 min at room temperature. Then, 50 nM MDL29,951, a GPR17 agonist, was added to the cells. The inhibitory effect of various concentrations of the test compound was measured and the resulting pIC 50 was determined. All incubations were performed in duplicate and results were compared to concentration-response curves of GPR17 agonist and antagonist reference compounds. Analysis and curve fitting was performed in ActivityBase XE using the XLfit4 parametric logistic equation y=A+((BA) / (1+((C / x)^D))), where A, B, C, and D are the minimum y, maximum y, and IC, respectively. 50 , which represents the gradient.

[0383] Ca 2+ Assay Results: Ca 2+ When tested in the recruitment assay, the compounds of the Examples typically have a pIC of 6.5 or greater, more preferably 7.5 or greater, and even more preferably 8.5 or greater. 50 The activity of the tested Example compounds is shown in Table 3 in Section B-IIB below. Activity ranges A, B, and C are 2+ Assay pIC 50 The values ​​are referenced as follows: "A":pIC 50 6.5≦x<7.5, "B": pIC 50 7.5≦x<8.5, “C”:8.5≦pIC 50

[0384] B-IIB. cAMP accumulation functional assay Activation of GPR17 can also recruit Gi-type G-protein signaling, resulting in a decrease in intracellular cyclic adenosine monophosphate (cAMP). Changes in intracellular cAMP can be measured using the HTRF cAMP dynamic assay kit from CisBio (Codolet, France). Using homogeneous time-resolved fluorescence technology (HTRF), the assay is based on the competition between native cAMP produced by the cells and cAMP labeled with the dye d2. Tracer binding was determined by an anti-cAMP antibody labeled with cryptate.

[0385] cAMP Assay Description CHO hGPR17 were dissociated in PBS containing EDTA and dispatched to black 384-well plates containing 5,000 cells per well. Cells were first incubated for 30 min at room temperature in HBSS Hepes (pH 7.4) containing vehicle or various concentrations of test GPR17 antagonist / inverse agonist compounds. Dose-response curves of MDL29,951 GPR17 agonists (usually 10 -5 M to 10 -10 M) was added to vehicle and the concentration of GPR17 antagonist / inverse agonist compound in each test was brought to a final volume of 20 μL of HBSS Hepes buffer (pH 7.4) containing 1% DMSO, 5 μM forskolin and 0.1 mM IBMX. After 60 min incubation at room temperature, the reaction is stopped and cells are lysed by adding d2 detection reagent and cryptate reagent in 10 μL each of lysis buffer according to the manufacturer's instructions. After 60 min incubation, changes in cAMP concentration are measured according to the manufacturer's instructions using an Envision plate reader equipped with laser excitation. All incubations were performed in duplicate. Data are presented as MDL29,951 pEC in the absence and presence of GPR17 antagonist / inverse agonist test compounds. 50The affinity of GPR17 antagonists / inverse agonists was determined by plotting the dose ratio (DR) versus antagonist concentration and analyzing the effect of schizophrenia on the affinity of GPR17 antagonists / inverse agonists.

[0386] cAMP Assay Results: When tested in the cAMP assay, the compounds of the examples typically exhibit pA2 values ​​of 6.5 or more, preferably 7.5 or more, more preferably 8.5 or more. The activities of the compounds of the examples that were tested are shown in the table below. Activity ranges A, B, and C refer to the pA2 values ​​of the cAMP assay as follows: "A": pA26.5≦x<7.5, "B": pA27.5≦x<8.5, "C": 8.5≦pA2.

[0387] The following Table 3 shows the Ca 2+ and pIC of the Example Compounds Tested in the cAMP Assay 50 and pA2 values ​​are shown. pA2 or Ca 2+ A blank in an assay column indicates that the respective compound has not yet been tested in the respective assay or that results are not yet available.

[0388] [Table 3]

[0389] B-IIC: Oligodendrocyte maturation / myelination assay The effect of negative modulators of GPR17 on primary oligodendrocyte maturation / myelination can be assessed in vitro by immunoassay using an antibody against myelin basic protein (MBP) as a marker for mature oligodendrocytes.

[0390] Description of the MBP Western Blot / Oligodendrocyte / Myelination Assay After 3–4 days in growth medium, rat primary OPCs were plated at 1 cm in 12-well tissue culture plates.2 Cells were seeded at 25,000 cells per well and switched to growth factor-free Neurobasal medium to induce spontaneous in vitro differentiation and GPR17 protein expression. After 24–48 h, growth factor-free medium was supplemented with 0.20 ng / mL triiodothyronine (T3) and 10 ng / mL ciliary neurotrophic factor along with 1 μM GPR17 antagonist / inverse agonist test compound or vehicle for an additional 3 days for cell culture. After compound treatment, cells were washed twice with ice-cold PBS and lysed in ice-cold lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% IGEPAL) supplemented with a protease inhibitor mixture. Lysates were spun at 4 °C for 20 min and centrifuged at 15,000 x g for 10 min at 4 °C. Protein concentrations were determined using the Pierce BCA Protein Assay according to the manufacturer's instructions. 7.5–15 μg of protein was separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes by electroblotting. After washing, the membranes were blocked with Roti-Block for 1 h at room temperature and incubated overnight at 4°C in Roti-Block containing MBP antibody (1:5000, LifeSpan BioSciences). The membranes were washed three times with PBS containing 0.1% Tween and then incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibody in Roti-Block for 1 h at room temperature. Immunoreactive proteins were visualized by chemiluminescence using Amersham Biosciences ECL Prime Western blotting detection reagent and quantified by densitometry using Gelscan software. To normalize for equal loading and protein transfer, membranes were reprobed with an antibody against β-actin (1:2500, BioLegend; secondary antibody goat anti-rabbit IgG HRP (ABIN)). Changes in MBP expression levels in the presence of test compounds were compared to MBP expression in control conditions.

[0391] Description of the MBP Fiber Plate / Oligodendrocyte Maturation / Myelination Assay OPCs were placed in a Mimetix Aligned 96-well fiber plate (Electrospining company) at 1 cm 2 Cells were seeded at 16,000–22,000 cells per well. After 2 days in proliferation medium and 2 days in growth factor-free Neurobasal medium to induce spontaneous in vitro differentiation and GPR17 protein expression, vehicle or 1 μM antagonist / inverse agonist test compounds were added in terminal differentiation medium supplemented with 0.20 ng / mL triiodothyronine and 10 ng / mL ciliary neurotrophic factor for 6 days, and the medium was replaced after 3 days. Cells were then fixed with 4% paraformaldehyde, followed by washing with PBS, permeabilization with 0.1% Triton X-100 in PBS, and blocking with 10% goat serum and 1% bovine serum albumin in phosphate-buffered saline. MBP antibody was diluted in blocking buffer (1:2000) and incubated for 1 h at 37 °C. Cells were washed again with PBS and incubated with Cy2-labeled secondary antibody against mouse IgG (Millipore, 1:500) for 1 h. After washing with PBS, cells were stained with 0.2 μg / mL DAPI, washed again and mounted with Mowiol. Fluorescent images were taken using a Zeiss AxioObserver.Z1 microscope equipped with an ApoTome Imaging System and a Plan-Apochromat 20x / 0.8 objective, eGFP filter (excitation 470 / 40 nm, emission 525 / 50 nm) and DAPI filter (excitation 365 nm; emission 445 / 50 nm). At least 15 random fields of control (terminal differentiation medium containing 0.1% DMSO) and test compounds were imaged using the same settings processed with Zeiss ZEN2.3 software. Changes in the number of myelinated fibers were reported by fiber length groups (0–40 μm, 41–60 μm, 61–80, 81–100, 101–120, and >120 μm) in the absence or presence of GPR17 negative modulators.

Claims

1. Compounds of Formula I 【Chemistry 1】 During the ceremony X1 is N or =C(R7)-; X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is C １‐６ Alkyl, C ３‐５ Cycloalkyl, and C ３‐５ heterocycloalkyl, each of which is selected from halogen, hydroxy, oxo, azido, cyano, carboxy, and C １‐３ Optionally substituted with one or more substituents selected from alkoxy, １‐３ ) the alkoxy can be unsubstituted or substituted with one or two groups selected from halogen, oxo, hydroxy, and carboxy; R2 is hydrogen or fluoro; R4 is hydrogen or fluoro; R5 is hydrogen or halogen; R6 is halogen, cyano, cyclopropyl, C １‐３ Alkyl, and C １‐３ alkyloxy, any alkyl or alkyloxy being optionally substituted with one or more fluorine atoms; R7 is hydrogen, halogen, C １‐２ Alkyl, Fluoro C １‐２ Alkyl, C １‐２ Alkoxy, Fluoro C １‐２ selected from alkoxy, cyclopropyl and cyclopropyloxy; R8 is selected from hydrogen, fluoro and methoxy; R9 is hydrogen or fluoro; R10 is halogen, cyano, cyanomethyl, cyclopropyl, and halogen, C １‐３ Alkyloxy and fluoro(C １‐３ ) alkyloxy; １‐３ alkyloxy; R11 is selected from hydrogen, fluoro and methoxy; R12 is hydrogen or fluoro; and pharma-ceutically acceptable salts and solvates thereof.

2. The compound according to claim 1, wherein X2 and X3 are not both nitrogen at the same time.

3. R1 is C １‐３ 3. The compound of claim 1 or 2, which is alkyl, optionally substituted with 1 to 4 substituents selected from hydroxy, carboxy, fluoro, fluoromethoxy, fluoroethoxy, hydroxymethoxy and hydroxyethoxy.

4. R1 is methyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, carboxymethyl, carboxyethyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorohydroxyethyl, fluorohydroxypropyl, and hydroxy(C １‐２ ) Alkoxy (C １‐２ 4. The compound according to claim 1 , wherein the aryl group is selected from the group consisting of aryl, aryl, aryl and aryl.

5. 5. A compound according to any one of claims 1 to 4, wherein R10 is selected from chloro, bromo, fluoromethoxy, fluoroethoxy, fluoromethoxyethoxy, fluoroethoxymethoxy and fluoroethoxyethoxy.

6. 6. The compound of claim 1, wherein R6 is selected from fluoro, chloro, bromo, cyano, methyl, methoxy, fluoromethyl, fluoromethoxy, cyclopropyl, and isopropyl.

7. The compound of claim 1 having the formula Ia: 【Chemistry 2】 During the ceremony X1 is N or -C(R7)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R7 is hydrogen or fluoro; R8 is selected from hydrogen, fluoro and methoxy; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; １‐２ alkyloxy; R11 is selected from hydrogen, fluoro and methoxy; R12 is hydrogen or fluoro; and pharma-ceutically acceptable salts and solvates thereof.

8. The compound of claim 1 having the formula Ib, 【Chemistry 3】 During the ceremony X1 is N or -C(R7)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is halogen, methyl, cyclopropyl, cyano, C １‐３ Alkyl, and C １‐３ alkyloxy, any alkyl or alkyloxy optionally being substituted with one or more fluorine atoms; R7 is selected from hydrogen, fluoro, chloro, fluoromethyl, and fluoromethoxy; R8 is selected from hydrogen, fluoro, and methoxy; R9 is hydrogen or fluoro; R10 is halogen, halogen, C １‐２ Alkyloxy and fluoro(C １‐２ ) alkyloxy; １‐３ alkyloxy; R11 is selected from hydrogen, fluoro, and methoxy; R12 is hydrogen or fluoro; and pharma-ceutically acceptable salts and solvates thereof.

9. The compound of claim 1 having the formula Ic, 【Chemistry 4】 During the ceremony X1 is N or =C(R7)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R7 is hydrogen; R8 is selected from hydrogen, fluoro, and methoxy; R9 is hydrogen or fluoro; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; １‐２ alkyloxy; R11 is selected from hydrogen, fluoro, and methoxy; and pharma-ceutically acceptable salts and solvates thereof.

10. A compound according to any one of claims 1 to 9, wherein X1 is N and has formula II. 【Chemistry 5】 In the formula, X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R8 is selected from hydrogen, fluoro, and methoxy; R9 is hydrogen or fluorine; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; １‐２ alkyloxy; R11 is selected from hydrogen, fluoro, and methoxy; R12 is hydrogen or fluoro; wherein X2 and X3 are not both nitrogen at the same time; and pharma-ceutically acceptable salts and solvates thereof.

11. A compound according to claim 1 or 10 having the formula IIa, IIb or IIc, 【Chemistry 6】 During the ceremony R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R8 is selected from fluoro and methoxy; R9 is hydrogen; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; １‐２ alkyloxy; R11 is selected from fluoro and methoxy; R12 is hydrogen; and pharma-ceutically acceptable salts and solvates thereof.

12. The compound of claim 1 having formula III: 【Chemistry 7】 During the ceremony X2 is N or =C(R12)-; X3 is N or =C(R9)-; R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R7 is hydrogen, fluoro or chloro; R8 is selected from hydrogen, fluoro, and methoxy; R9 is hydrogen or fluoro; R10 is optionally substituted with 1 to 3 substituents selected from halogen, fluoro, methoxy, and fluoromethoxy; １‐２ alkyloxy; R11 is selected from hydrogen, fluoro, and methoxy; R12 is hydrogen or fluoro; where X2 and X3 are not both nitrogen at the same time; and pharma-ceutically acceptable salts and solvates thereof.

13. A compound according to claim 1 or 12 having the formula IIIa, IIIb or IIIc: 【Chemistry 8】 During the ceremony R1 is unsubstituted or selected from the group consisting of fluoro, hydroxy, carboxy and C １‐２ C substituted with one or more substituents independently selected from alkoxy １‐３ alkyl, C １‐２ The alkoxy can be unsubstituted or substituted with one or more substituents selected from carboxy, fluoro and hydroxy. R2, R4, and R5 are all hydrogen; R6 is selected from halogen, methyl, cyclopropyl, cyano, fluoromethoxy and fluoromethyl; R7 is hydrogen; R8 is selected from fluoro and methoxy; R9 is hydrogen; R10 is selected from fluoro, chloro, bromo, fluoromethoxy, and fluoroethoxy; R11 is selected from fluoro and methoxy; R12 is hydrogen or fluoro; and pharma-ceutically acceptable salts and solvates thereof.

14. A compound according to any one of claims 1 to 13, wherein R1 is C １‐３ Alkyl and (C １‐２ ) Alkoxy (C １‐２ ) alkyl, each of which is optionally substituted with 1 to 4 substituents selected from hydroxy and fluoro; R2, R4, R5, R7 (if present), R9 and R12 (if present) are all hydrogen; R6 is selected from fluoro, chloro, bromo, fluoromethoxy, and fluoromethyl; R8 is selected from fluoro and methoxy; R10 is halogen and fluoro(C １‐３ ) alkoxy; R11 is fluoro or methoxy; and pharma-ceutically acceptable salts and solvates thereof.

15. 15. A compound according to any one of claims 1 to 14, wherein R6 is selected from chloro and bromo.

16. The compound according to claim 1, wherein the compound is selected from the group consisting of: N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-fluoro-3-hydroxypropyl)indole-3-sulfonamide, 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3,3,3-trifluoro-2-hydroxypropyl)indole-3-sulfonamide, 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,2-difluoroethyl)indole-3-sulfonamide, 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-(2,3-dihydroxypropyl)indole-3-sulfonamide, 6-chloro-N-(6-chloro-5-fluoro-2-methoxypyridin-3-yl)-1-methylindole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(3-fluoro-2-hydroxypropyl)indole-3-sulfonamide, 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2,3-dihydroxypropyl)indole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxypropyl)indole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide, 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylpyrrolo[2,3-b]pyridine-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)pyrrolo[2,3-b]pyridine-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-[2-(2-hydroxyethoxy)ethyl]indole-3-sulfonamide, 6-chloro-N-[6-(difluoromethoxy)-5-fluoro-2-methoxypyridin-3-yl]-1-(2-hydroxyethyl)pyrrolo[2,3-b]pyridine-3-sulfonamide, 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-fluoroethyl)indole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2,3-dihydroxypropyl)indole-3-sulfonamide, 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-methylindole-3-sulfonamide, 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1-(2-hydroxyethyl)indole-3-sulfonamide, N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-methylindole-3-sulfonamide, 2-[3-[(4-bromo-2,5-difluorophenyl)sulfamoyl]-6-chloroindol-1-yl]acetic acid, and N-(4-bromo-2,5-difluorophenyl)-6-chloro-1-(2-hydroxyethyl)indole-3-sulfonamide.

17. A pharmaceutical composition comprising any of the compounds according to any one of claims 1 to 16 and at least one pharma- ceutically acceptable carrier.

18. A compound according to any one of claims 1 to 16 for use in therapy.

19. A compound according to any one of claims 1 to 16 for use in the treatment of a demyelinating disorder, wherein the demyelinating disorder is multiple sclerosis.

Images